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3 ABSTRACT
3 Abstract
Stem Cells (SCs) may play a critical role in cancer development, yet the direct demonstration is still lack-
ing. The characterization of mechanisms that sustain and regulate Cancer Stem Cells (CSCs) may help
elucidating their role in tumors. Using a MMTV-ErbB2 breast cancer mouse-model, we had previously
shown that CSCs, through multiple rounds of symmetric divisions and extended self-renewal, drive tumor
growth and the expansion of the CSC pool. Critical for this property is the lack of functional p53, that
drives CSCs to symmetric divisions. Here we show that symmetric divisions and extended self-renewal in
CSCs are due to the activation of c-myc as direct consequence of the loss of functional p53. In particular,
c-myc is upregulated in transformed and p53-/- immortalized SCs, and enforced expression of c-myc in
normal mammary SCs induces symmetric divisions and extended self-renewal, but does not transform.
We show that mammary progenitors expressing c-myc acquire in vitro self-renewal properties (mammo-
sphere formation and expansion) and in vivo regenerative potential (formation of normal mammary gland
upon transplantation). Our data suggest that c-myc is critical for the maintenance of CSCs in ErbB2-
mammary tumors and their aberrant self-renewing properties. This is achieved through its binary effect
on CSCs (induction of symmetric divisions) and progenitors (reprogramming into CSCs). Recent studies
demonstrate that c-myc over-expression in epithelial tissues induces an abnormal transcriptional pattern,
similar to that of embryonic SCs, and that the same is activated in epithelial cancers and CSCs. This
suggests that c-myc may be a general regulator of CSCs and their altered self-renewing properties.
xii
4 INTRODUCTION
4 INTRODUCTION
4.1 The Origin and Nature of Cancer
Cancer is a widespread disease that comprises a number of different lesions characterised by uncontrolled
cell proliferation. What univocally describes these lesions is their very heterogeneity. Not only they
can arise in different tissues with different mechanisms, but within each single lesion cells with several
phenotypical and functional differences coexist (Campbell and Polyak, 2007; Reya et al., 2001; Visvader
and Lindeman, 2008). These cellular subtypes differ in size and morphology, cell surface marker expression,
membrane composition as well as in proliferation rate, cell-cell interaction, metastatic proclivity, and
sensitivity to chemotherapy. Three models have been postulated to explain the underlying mechanisms
and to describe the onset and progression of cancer: the cancer stem cell model, the clonal evolution model
and the interconversion model. These theories have important implications from a therapeutic point of
view, as they identify very different putative targets for therapies that can be specifically directed against
those cells that contribute to the progression of the disease.
4.1.1 The Cancer Stem Cell Theory
The CSC theory postulates that only a subset of cells that possess stem properties accounts for the
maintenance and the growth of a tumoural mass .SCs are a long-lived cell population responsible for
tissue formation, homeostasis and repair. SCs have been identified in several tissues like blood, breast,
colon, lung, liver and brain but, in light of recent findings, it seems plausible that every tissue is maintained
by specific SCs. These cells are defined by their ability to perpetuate themselves through self-renewal
and to generate mature cells of a particular tissue through differentiation. Because tumours can be
considered as hierarchically organized tissues, it is reasonable to propose that a subset of cells with
analogous properties is responsible for the sustenance of the malignant cellular mass. Due to their extended
life span, normal SCs or their direct progenies represent an ideal target of cell transformation, and may
explain the appearance of CSCs (Fig. 4.1) .
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Figure 4.1: The Cancer Stem Cell Theory.
In the cancer stem cell theory, the only tumorigenic cells, CSCs, are able to sustain their growth (outlined
arrow) and to give rise to differentiated cells (Pr) that cannot support the growth of the tumour mass (in
red).
Therefore, according to this theory, cancers are supported by transformed SCs, which retain the same
self-renewing and differentiating properties of their normal counterparts (Reya et al., 2001; Shipitsin
and Polyak, 2008). Just as normal SCs, they can differentiate into phenotypically different progeny
with limited proliferative potential through irreversible epigenetic changes that are accompanied by the
loss of tumorigenic capacities. Consistently with this model, several tumours have been shown to be
subfractionable into populations of tumorigenic and non tumorigenic cells, suggesting that indeed there
is a phenotipic and functional hierarchy within the tumour mass.
The first demonstration of the existence of a rare population of cancer-initiating cells came from
studies performed in 1994 on acute myeloid leukemia (AML) patients, by the group of John Dick in
Toronto (Lapidot et al., 1994). In this study, the authors describe the purification of a subpopulation of
cancer cells that possess tumour-initiating properties. Using the fluorescence-activated cell sorting (FACS)
technique, they were able to fractionate different subsets of tumour cells based on the expression of surface
markers. Of these subpopulations, only the CD34 +/CD38- cell fraction was able to form a new AML upon
xeno-transplantation in mice, leading to the formal demonstration that only specific cell subsets in the
tumour mass were able to recapitulate the disease upon engraftment. These cells showed differentiating
and self-renewing abilities, as they were able to form tumours with the same cell heterogeneity of the
2
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tumour of origin, and could be serially transplanted to obtain tertiary tumours. In addition, the surface
markers that prospectively identified the AML-initiating cells were found to be specifically expressed in
the corresponding normal SCs. Because these AML-initiating cells represented less than the 0,01% of the
total leukemia cells, the authors concluded that rare cells in tumours share the same features of normal
SCs and can be referred to as Cancer SCs (Campbell and Polyak, 2007; Visvader and Lindeman, 2008).
Further evidences supporting the CSC theory have come from several human diseases including ma-
lignant germ cell cancers (Illmensee and Mintz, 1976; KLEINSMITH and PIERCE, 1964), breast cancers
(Al-Hajj et al., 2003), brain cancers (Singh et al., 2004) and colon cancers (Ricci-Vitiani et al., 2007;
O’Brien, 2007; Dalerba et al., 2007). All these works describe the identification of a subpopulation of cells
isolated from the bulk of the tumour mass which possessed the ability to reproduce the disease if engrafted
in recipient mice. In particular, the identification of cancer cells with stem properties in breast cancers was
the first report of the existence of these cells in solid malignancies. In 2003 Al-Hajj and colleagues isolated
from human breast cancer samples a CD44+/ CD24- population that was highly enriched in cells able to
re-generate breast carcinoma upon transplantation into the mammary tissue of NOD-SCID mice (Al-Hajj
et al., 2003). This work made way for the subsequent identification of cell surface markers that have been
used to purify human cancer SCs in different tumours . Although it is still unclear whether all cancers
exhibit the same hierarchical organization and are sustained by cells with stem properties, some of the
identified markers were found to be expressed by cancer SCs derived from different types of tumours. For
example, CD44 has been used to fractionate cancer SCs in breast, colon and pancreas tumours, whereas
CD133 can separate cancer SC subsets in brain (both glioblastoma and medulloblastoma), colon, pancreas
and lung tumours. Interestingly, CD44 is expressed in a variety of epithelial basal layer cells, where SCs
and less differentiated precursors are usually situated (Tan et al., 2006), and CD133 is also expressed in
normal neural SCs (Uchida et al., 2000), thus supporting the idea that cancer SCs may arise from the
transformation of normal SCs or their direct progenies.
In summary, the CSC hypothesis implies that a particular subset of tumour cells with stem cell-like
properties drives tumour initiation, progression, and is responsible for the high recurrence incidence of
this malignancy. These cells share with normal adult SCs the ability to self-renew indefinitely and to
differentiate, two properties that lead to the generation of nontumorigenic differentiated cells, thereby
accounting for tumour heterogeneity. Because of the described similarities, the origin of CSCs is often
attributed to the transformation of normal SCs, although there is no formal proof to confirm this. These
cells are thought to persist as a small fraction of the total cells in the tumour and to sustain its growth
with their constant expansion (Visvader and Lindeman, 2008; Campbell and Polyak, 2007).
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4.1.2 The Clonal Evolution Model
The CSC theory is supported by very strong data, however, there are some limitations to this theory
and some of its points still remain to be demonstrated. As previously described, this theory identifies a
small subset of tumour cells as responsible for tumour growth and sustenance. According to the model,
these cells are the only ones that can propagate the disease if transplanted, however, recapitulation of the
heterogeneity of the original tumour upon transplantation has only ever been evaluated by the analysis of
few surface markers, and genetic alterations in the primary tumour has never been studied. Furthermore,
transplantation in NOD/SCID mice of human tumour cells has been shown to dramatically underestimate
the frequency of tumorigenic cells in some cancers (Quintana et al., 2008) suggesting that the population
of tumorigenic cells may be dramatically underestimated. The CSC theory postulates that CSCs are
responsible for the tumour growth and they can originate differentiated progeny which has undergone
epigenetic modifications and is no longer tumorigenic. Nonetheless, the observed tumour heterogeneity,
in fact, can arise also if cells that compose it differ genetically rather than epigenetically, and these genetic
alterations may result in the loss of tumorigenicity (Shackleton et al., 2009). If this were the case, the
process of tumour formation and growth may be explained by a model that identifies as potential target
of transformation any cell in a given tissue. Transformation occurs through the accumulation of multiple
stochastic genetic mutations and results in the generation of an heterogeneous population of cancer cells
within the same tumour; this model has been named the clonal evolution model (Fig. 4.2).
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Figure 4.2: The Clonal Evolution Model.
In the clonal evolution model, phenotypically distinct cancer cells are endowed with the same malignant
potential and the potential to propagate themselves (outlined arrows), and are equally likely to acquire
the ability to propagate the tumour (in red) by accumulation of further genetic mutations (bolts).
Based on this theory, different subpopulations arise continuously within the tumour mass by accumu-
lation of mutations of genes that control cellular checkpoints, which favors the onset of additional genetic
mutations and the selection of new phenotipic traits, thus accounting for tumour heterogeneity. Further-
more, any new mutation can potentially increase invasiveness, thus conferring to the tumour metastatic
properties or resistance to therapies (Campbell and Polyak, 2007).
In summary, the clonal evolution model states that heterogeneity in a tumoural mass may not be
necessarily due to a hierarchical organization of cells. Accumulation of genetic mutations and epigenetic
modifications can account for the generation of subpopulations with different phenotype, function and
response to therapy. The clonal evolution model can explain several tumour features, including its clonal
origin, morphological and functional heterogeneity, tumour progression, metastasis and reoccurrence.
4.1.3 The Interconversion Model
A third and more novel model for cancer development hypothesises that cancer cells may interconvert
between different tumorigenic states. This model has been proposed in response to the CSC tumour
model as more and more evidences suggest that the fraction of CSCs in human tumours (defined as
tumorigenic cells capable of spawning non-tumorigenic cells) may not be as exiguous as the current SC-
validation methods allow to establish. Moreover, the number of CSCs in a tumour may vary depending
on the level of its differentiation, within different subtypes arising from the same tissues and in the same
tumour in response to factors that are intrinsic or extrinsic to the cells of origin like cell type, stromal
microenvironment, somatic mutations and stage of tumour progression (Gupta et al., 2009). In light
of these observations, it has been proposed that cancer cells may exist in two phenotypical states with
different tumorigenic potential. The acquisition of tumorigenic and metastatic potential has been often
associated with a specific state of differentiation at least in the mammary gland. Accordingly, epithelial
to mesenchimal transition (EMT) in transformed cells induces the enrichment in CSCs(Morel et al., 2008;
Mani et al., 2008). Interestingly, EMT has been shown to be a reversible process, that can be undone upon
removal of the environmental cues that initially triggered it (Hugo et al., 2007). This cellular plasticity
may occur also in the context of CSCs, generating cells that are endowed with tumorigenic potential or
that are unable to sustain tumour growth depending on their differentiation state and ultimately on the
stimuli that they receive from their microenvironment. Indeed, analogous mechanisms may also govern
normal tissues. A first suggestion of the existence of this mechanism comes from intra-vital studies
of melanomas where researchers have shown oscillation between metastatic and non-metastatic status,
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expression of stem-associated gene Brn-2 and pigmentation of melanoma cells (Pinner et al., 2009) (Fig.
4.3).
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Figure 4.3: The Interconversion Model.
In the interconversion model cells with tumorigenic abilities (blue) give rise to more differentiated cells
(yellow) with no potential to sustain the tumour mass (in red). However, in response to external cues
and depending on their differentiation state, these cells are able to convert to tumorigenic cells (jagged
arrow).
Because all three theories are supported experimental evidences, it is reasonable to hypothesise that
all the above mechanisms coexist during tumour growth. In fact, tumours that follow a CSC model may
contain cells that undergo clonal selection during self-renewal and differentiation, and the non-tumorigenic
cells that they originate may acquire further mutations that somehow restore self-renewing and cancer-
promoting abilities through genetic changes and epigenetic alterations. The result of this scenario is an
heterogeneous population of cancer cells that dominate the tumour growth and continuously reiterate
processes of mutation and differentiation, giving rise to all tumour cell types.
Regardless of the origin of the cells that comprise the tumoural mass and of the mechanisms with which
they evolve, it is clear that tumours arise because of the existence of cells with deregulated self-renewing
mechanisms. This is why the study of self-renewal in SCs may help the understanding of the alterations
that are at the basis of carcinogenesis.
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4.2 Pathophysiology of Breast Stem Cells
4.2.1 Stem Cells in Breast Tissues
The existence of mammary SCs has been first described by Deome et al. in 1959, with transplantation
studies on mice that showed how cells with the ability to repopulate a mammary gland could be found in
adult tissues (DEOME et al., 1959). Several years later, Kordon and Smith showed in a very elegant, yet
indirect, way how the mouse mammary gland can be repopulated by a single cell and that the mammary
epithelium contains three distinct multipotent progenitors(Kordon and Smith, 1998). These studies paved
the way for many others and have rendered the mammary gland, especially in the mouse, a very potent
system for the study of SCs and their role in tissue homeostasis as well as in cancer.
There are five pairs of mammary glands in the mouse. These comprise two different cellular com-
partments: the epithelium, which consists of ductal and alveolar cells, and the stroma, also called the
mammary fat pad, that is composed mainly of adipocytes, but also of other cell types, like fibroblasts,
haematopoietic cells, blood vessels and neurons. The epithelial cells are organized into a system of
branched ducts that progressively decrease in diameter and terminate in lobular complexes of alveoli.
Ducts and alveoli possess a central lumen that opens to the body surface through the nipple. In the
alveoli, the luminal epithelial cells undergo functional differentiation during pregnancy to produce milk.
The basal myoepithelial cells, whose contraction facilitates the milk release, surround both ducts and
alveoli. This complex system of ducts and alveoli is embedded in the mammary fat pad (Hennighausen
and Robinson, 2001, 2005; Smalley and Ashworth, 2003) (Fig. 4.4).
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Figure 4.4: Structure of the mammary gland.
The mammary epithelial tree is organized in a series of ducts that terminate in alveolar clusters. These
structures have a hollow lumen paved with luminal epithelial cells (red) that are responsible for the
secretion of milk during lactation. The system of basal myoepithelial cells (yellow) that surround the
ducts and alveoli favour the milk secretion with their contraction. The complex structure of ducts convey
to the nipple, where the milk is expelled. The mammary epithelium is embedded in a fat-pad comprised
by adipose cells, but also other stromal components and blood vessels, that sustain its growth.
The mammary gland undergoes massive rearrangements in defined stages that are connected to sexual
development and reproduction. These are embryonic, prepuberal, puberal, pregnancy, lactation and
involution. During puberty the epithelial ducts grow and branch further, to reach a complete penetration
of the fat pad in maturity. During pregnancy, the alveolar compartment expands and matures, and is
the site of milk secretion during lactation. Lactation is followed by an involution stage, during which the
alveoli undergo apoptosis and remodeling to restore a simple ductal structure. Alveolar expansion and
maturation, lactation and involution initiate with every new pregnancy (Smalley and Ashworth, 2003;
Hennighausen and Robinson, 2001, 2005). The complex turnover that characterizes the mammary gland
is a functional proof of the existence of cells endowed with the ability to sustain and regenerate the tissue
for several cycles. Such cells are responsible for the generation of all the cells that form the epithelial
compartment of the gland. They have the capacity to self-renew and give rise to progenitor cells destined
to either a basal or a luminal fate. It is generally believed that in the mammary gland of puberal mice
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these SCs reside in the terminal end buds (TEBs), the growing units at the end of the ducts. TEBs are
composed of a mass of cells surrounded by a layer of cap cells that are the putative SCs. Cap cells generate
transit cells on the outer side of the TEB that will differentiate in the myoepithelium, and transit cells
that form the body cells and will differentiate into luminal epithelial cells. The ductal lumen is formed
following apoptotic events in the mass of the developing body/luminal cells. TEBs disappear at the end
of the puberty, when the mammary gland reaches its full development (Smalley and Ashworth, 2003).
Great effort has been put into the isolation of mammary SCs in the past few years, and the use of
different methods has led several research groups to purify a population of cells highly enriched in cells
with stem properties. These include: i) the side-population method, which relies on the increased activity
of membrane transporters that is specific to SCs and enables their isolation based on dye exclusion assays
(Alvi et al., 2003); ii) FACS sorting of SCs based on the expression of surface markers as pioneered by the
haematopoietic system; iii) the mammosphere culturing system, which, based on an analogous protocol
used for neural stem cells, enriches the cell population in stem and progenitor cells.
All the methods mentioned above and all the surface markers that have been described for the purifi-
cation of mammary SCs allow for the isolation of a population of cells enriched in SCs, nevertheless, no
technique has been established for the identification of bona fide SCs.
4.2.2 Breast Cancer Stem Cells
In the last few years we have witnessed a drastic reduction in the mortality of breast cancer patients.
This has been possible due to the improvement in the techniques for early detection and the use of more
effective adjuvant therapies and therapies that efficiently target specific molecular subtypes of this disease.
Nevertheless, many women affected by this malignancy experience relapse after treatment, a phenomenon
that renders metastatic breast cancer a widely incurable disease. The high frequency of relapses in breast
cancers, as well as in many other types of cancer, has been attributed to the presence of a subset of
cells that escape these treatments, thanks to properties that render them similar to SCs. This is why
understanding the properties of normal SCs may shed light on the alterations that these cancer SCs
undergo and may help in defining targeted therapies against these cells.
The human breast cancer was the first solid malignancy for which the cancer stem model was described.
Breast cancer SCs were isolated based on the expression of the cell surface markers ESA and CD44
and on the absence of CD24(Al-Hajj et al., 2003). Since then other markers have been described to
isolate human breast CSCs, as for example the expression of aldehyde dehydrogenase (ALDH)(Ginestier
et al., 2007), however, there are evidences that show that different breast cancers are sustained by CSCs
that express different cell surface markers(Charafe-Jauffret et al., 2009; Wright et al., 2008). Because
very little is known about cell surface markers that may allow for a perspective identification of normal
and tumour human breast SCs (Cariati and Purushotham, 2008), and because the expression of surface
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markers is highly dependent on the cell microenvironment, other methods that rely on the functional
characterization of CSCs have been adopted. Taking advantage of protocols that have been established
for neural SCs (Reynolds and Weiss, 1996; Weiss et al., 1996), a population enriched in SCs was isolated
from the normal mammary gland and propagated in vitro as non-adherent spheroids called mammospheres.
Mammospheres are enriched in undifferentiated cells that: i) are able to growth in anchorage-independent
manner, ii) can be serially propagated showing self-renewal ability and iii) are capable of multilineage
differentiation upon plating in a differentiation-promoting matrix (Dontu et al., 2003). Interestingly,
mammospheres arising from primary human breast tumours are composed of cells that show a CD44+/
CD24- phenotype and are greatly enriched in tumour initiating cells, thus indicating that mammosphere
assay is also a good system to propagate cancer SCs (Ponti et al., 2005). All the methods that have been
adopted for the purification of tumour SCs rely on the potent tool that the mammary gland offers, to
validate the stem properties of mammary epithelial cells based on their ability to repopulate the cleared
fat pad upon xenotransplantation in the mammary gland of immunocompromised mice. Although this
technique is considered the gold standard assay for the validation od CSCs, it does not take into account
the role that the immune system plays in regulating cancer onset and progression, suggesting that indeed
this method may have some important limitations.
Table 4.1: Prospective isolation of CSCs from different tumour types based on the expression
of surface markers.
Cancer subpopulations enriched in CSCs have been isolated from different tumour subtypes and the pres-
ence of tumorigenic cells evaluated by transplantation in immunocompromised mice. The table indicates
the enrichment of cancer-forming cells as percentage of cells expressing the CSC marker and the mini-
mum number of cells required for the development of tumours in recipient mice(adapted from Visvader
and Lindeman, 2008).
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It was recently shown in a variety of transgenic mouse models that murine mammary tumours too follow
a CSC model. Various degrees of cancer SC enrichment, in fact, were documented in the CD24posThy1pos
(Cho et al., 2008) or CD29lowCD24posCD61pos (Vaillant et al., 2008) breast cancer fractions from MMTV-
Wnt-1 transgenic mice; in the CD24highCD29high(Zhang et al., 2008) or CD29lowCD24posCD61pos breast
cancer fractions from p53-null mice; and in the CD24pos breast cancer fraction from transgenic mice
overexpressing the non-mutated form of ErbB2 (Liu et al., 2007a), though the same was not observed
in another report (Vaillant et al., 2008). More recently, Grange and colleagues reported the prospective
isolation of cancer SCs from transgenic mice expressing the mutated form of ErbB2 (Grange et al., 2008).
In particular, they show enrichment of CSCs associated with positivity to the surface marker Sca1 (3
positive transplants out of 6 injections with 100 Sca1+ cells; no positive transplants out of 6 injections
with 10,000 Sca1− cells).
Collectively, these reports confirm the great heterogeneity of the markers expressed by CSCs in human
tumours as well as in transgenic mouse models, these markers being also often different from those
expressed by normal SCs. Moreover, in all the analyzed breast tumours derived from transgenic models,
except those from mutated ErbB2-transgenic mice, the negative subpopulations (those that did not express
the selected markers) were also able to transplant, although with a lower frequency compared to the
positive fractions, confirming the great heterogeneity of CSCs in tumour tissues.
4.2.3 Targeting Breast Cancer Stem Cells
The confirmation of the existence of cells with stem properties within the bulk of a tumour mass has
important therapeutic implications. Conventional anti cancer therapies rely on the property of tumour
cells to be actively proliferating; however, CSCs that like normal SCs are slowly dividing, survive this
kind of treatment and are likely to give rise to relapses (Gil et al., 2008; Reya et al., 2001; Visvader and
Lindeman, 2008).
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Figure 4.5: Effects of CSC-targeted treatments and conventional treatments.
It is believed that conventional treatments do not result in the elimination of CSCs that can repopulate
the tumour and give rise to relapses. Conversely, CSCs-specific treatments allow for the eradication of the
cells that sustain and promote the tumour growth, thereby resulting in the degeneration of the tumour
mass.
Indeed it has been shown in cell lines and primary tumours that CSCs are relatively more resistant to
radiation therapy and cytotoxic chemotherapy(Dave and Chang, 2009). Several mechanisms account for
the resistance of CSCs to antitumoural therapies. It has been shown that human CSCs possess lower levels
of pro-oxidants, thus rendering them resistant to radiation therapies(Dave and Chang, 2009). Further-
more, several molecular mechanisms that are active in CSCs have a protective role against chemotherapic
agents: expression of cellular transporters, such as the MDR1 and ABC transporters (Jordan et al.,
2006), high levels of anti-apoptotic proteins, such as those of the BCL-2 family (Al-Hajj et al., 2003; Reya
et al., 2001), or increased efficiency of the DNA repair machinery and alterations in the cell cycle kinetics.
Current therapies, though they may produce dramatic responses on the tumour mass, affect only the
differentiated progenies of CSCs and do not allow for long-term remissions because they do not target the
rare population of CSCs. This might explain why the tumour regression that results from conventional
treatments does not necessarily correlate with patient survival(Huff et al., 2006). CSC-targeted therapies
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that aim at the selective ablation of the these rare cells may therefore represent an attractive method to
definitively eradicate the tumour mass.
Indeed, resistance of CSCs to conventional treatments requires for the establishment of new approaches
that specifically target particular traits that are unique for these cells. One of the defining properties of
CSCs is their increased self-renewing ability. Self-renewal is a complex mechanism governed by several
pathways, including the Notch, Wnt and Hedgehog pathways. These pathways have been found to be
aberrant in several human breast cancers and, if altered, they are sufficient to induce the formation of
breast tumours in transgenic mouse models(Liu et al., 2005).
Currently, several evidences of a positive effect of CSC-based treatments have been produced in differ-
ent tissues. Many of these rely on the targeting of self-renewing mechanisms that are specific for CSCs,
and others induce differentiation of CSCs, disrupting their niche. For instance, targeting of the Hedgehog
pathway in Chronic Myeloid Leukemia (CML) mouse and human cells with the molecule cyclopamine
inhibited their growth in vitro(Zhao et al., 2009), and the same treatment was effective also on inhibiting
the tumorigenicity of human gliomas in mice(Clement et al., 2007). Similarly, inhibition of the Notch
pathway through blockage of the γ-secretases depleted CSCs in gliomas and medulloblastomas in trans-
genic mice and xenotransplants(Fan et al., 2006, 2010). Targeting of other molecules that are enriched or
activated in CSCs has proven effective in preventing tumour growth in vivo and survival of mice models,
and these include the tumour suppressor PML in Chronic Myeloid Leukemia (Ito et al., 2008), mTor with
rapamycin in mouse models of leukemia (Yilmaz et al., 2006), the NF-κB pathway in human leukemic
SCs (Guzman et al., 2002), IL-6 receptors (Wang et al., 2009), IL-3 receptor α(Jin et al., 2009), TGF-β
and LIF(Penuelas et al., 2009; Ikushima et al., 2009). Other strategies that induce differentiation of
CSCs, thus depleting their niche, include inhibition of the Wnt pathway in skin tumours which results
in tumour regression and is accompanied by terminal differentiation of the cancer cells (Malanchi et al.,
2008) and treatment of glioblastoma CSCs with bone morphogenetic proteins (BMP), which induces in
vitro differentiation, thus abolishing their tumour-forming ability. Accordingly, in vivo administration of
BMPs blocks the tumour growth and the mortality of mice transplanted with human glioblastoma cells
(Piccirillo et al., 2006).
4.3 Stem Cells and Self-Renewal
A key question in cancer biology is whether CSCs possess different growth potential, life span or drug
sensitivity compared to their normal counterparts and, more importantly, which are the relevant under-
lying molecular pathways. What is clear is the striking correlation between deregulated SC functions
and tumourigenesis: many oncogenes are activated forms of genes that promote self-renewal and cell
proliferation, and tumour suppressors are often genes that negatively regulate these processes.
CSCs share many properties with normal SCs, most notably their ability to self-renew and to give rise
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to cells that differentiate. These tasks can be accomplished through two different strategies: i) a pool
of SCs with equivalent developmental potential may divide symmetrically producing only identical SC in
some divisions and only identical differentiated cells in others or ii) a single SC can divide asymmetrically
through a single self-renewing mitotic division, in which one daughter cell retains the SC identity and
the ability to replicate almost indefinitely, while the other undergoes limited rounds of mitotic division
before entering a post-mitotic fully differentiated state (progenitor cells). The asymmetric cell division
allows, with a single division, both for self-renewal and differentiation; however, it leaves SCs unable to
expand in number. In order to expand their pool, SCs must adopt another type of self-renewing division,
one that generates two daughter cells with the same SC fate (symmetric division) (Morrison and Kimble,
2006) (Fig. 4.6).
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Figure 4.6: Types of stem cell divisions.
Different types of SC divisions have different effects on the SC pool.
4.3.1 Stem Cell Divisions
Asymmetric SC divisions have been initially observed in invertebrates such as the worm Caenorhabdi-
tis elegans and the fruit fly Drosophila melanogaster (Gonzalez, 2007; Januschke and Gonzalez, 2008;
Morrison and Kimble, 2006). Asymmetry of cell division can be achieved through intrinsic mechanisms
that involve the partitioning of cell fate determinants or through extrinsic mechanisms that rely on the
cross-talk between the dividing SC and its niche. Intrinsic mechanisms require the regulated and polarized
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assembly of cell polarity factors, such as the atypical protein kinase C (aPKC) and the partitioning factors
(PAR-3 and PAR-6), and the controlled segregation of cell fate determinants such as Numb and partner
of Numb (PON) or Brain tumour (Brat), Prospero (Pros) and their adaptor Miranda (Mira). Asymmet-
ric localization of the PAR–aPKC complexes at the apical cortex initiates the asymmetric division and
governs both asymmetric segregation of cell fate determinants, that accumulate to the opposite site of the
plasma membrane (basal cortex), and the assembly of the mitotic spindle along an apical-basal axis. The
regulated mitotic spindle orientation ensures the segregation of the cell polarity complex to one daughter,
which will retain SC fate, and the cell fate determinants to the other cell that will differentiate. Classic
examples of asymmetric divisions that are controlled by an intrinsic mechanism are provided by the C. el-
egans zygote (Morrison and Kimble, 2006) and the Drosophila larval neural SCs (Neuroblasts) (Gonzalez,
2007; Januschke and Gonzalez, 2008). The C. elegans zygote divides asymmetrically to produce one larger
blastomere which will originate the ectoderm, and one smaller blastomere that will produce the meso-
derm, endoderm and finally the germ line in a series of asymmetric divisions. The Drosophila neuroblast
divides into a large daughter cell that will retain SC fate and continue to divide asymmetrically, and a
small daughter cell that will become a ganglion mother cell (GMC) and divide once more, originating
cells that will differentiate as neurons or glia. Extrinsically regulated asymmetric divisions rely on the
asymmetric positioning of the two daughter cells in relation to the SC niche. This is achieved by the
regulated orientation of the mitotic spindle that ensures that only one of the daughter cells remains in the
niche (the SC), whereas the other cell is placed away from the niche and exposed to signals that induce
differentiation(Morrison and Kimble, 2006). A classic example of an asymmetric division controlled by
extrinsic mechanisms is provided by the male germline SCs of Drosophila. Male germline SCs are placed
adjacent to a cluster of postmitotic cells (hub cells) that form their niche and provide the signals that are
necessary for SC self-renewal. After the mitotic division, a male germline SC generates two daughter cells
of equal size, one of which remains close to the hub and retains SC identity, and the other, the gonialblast,
is placed away from the niche and enters a series of four mitotic divisions to produce the spermatocytes
(Gonzalez, 2007). Indeed these two mechanisms are not mutually exclusive and in some cases may coexist
to achieve asymmetry of SC division (Morrison and Kimble, 2006).
Some of the mechanisms of asymmetric division that have been described in invertebrates are conserved
in mammalian SCs. During the development of the mouse cortex, undifferentiated neural progenitors
asymmetrically distribute the fate determinant Numb to precursors destined for neurogenesis (Shen et al.,
2002). Numb is also asymmetrically distributed to progeny of cultured satellite muscle cells, where it
promotes myogenic differentiation of only one daughter cell (Shinin et al., 2006; Conboy and Rando,
2002). Thus, asymmetric segregation of Numb may be a conserved mechanism both in Drosophila and
vertebrates. Furthermore, both mammalian basal epidermal progenitors (Lechler and Fuchs, 2005) and
cortical ventricular zone neural progenitors (Chenn and McConnell, 1995) seem to regulate the orientation
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of mitotic spindles. The spindle orientation relies on the cortical localization of the PAR– aPKC complex
(Lechler and Fuchs, 2005), a mechanism that also controls the asymmetric division of Drosophila and C.
elegans SCs (Morrison and Kimble, 2006).
Symmetric SC divisions result in an increase in the number of SCs. They are adopted by both
vertebrates and invertebrates to form or regenerate tissues during development or after injury. Several ex-
amples of symmetric divisions during tissue development have been described. During larval development
of C.elegans, symmetric divisions occur in the germ line SCs to develop the pool of undifferentiated germ
cells and differentiated gametes (Morrison and Kimble, 2006). Mammalian SCs too undergo symmetric
divisions during embryonic or early fetal development. Although direct imaging of these divisions is still
lacking, researchers have shown that mouse haematopoietic SCs double in number every day in the fetal
liver until 14,5 days post-coitus, suggesting that they undergo symmetric divisions (Morrison et al., 1995).
In other systems like undifferentiated neural progenitors in the developing mouse cerebral cortex (Chenn
and McConnell, 1995; Huttner and Kosodo, 2005; Noctor et al., 2004) or cells in the basal layer of the
fetal epidermis (Lechler and Fuchs, 2005) direct imaging has confirmed symmetry of divisions. In both
cases the expansion in the pool of undifferentiated progenitors was the result of divisions that generated
two morphologically identical daughter cells that remained undifferentiated, although no proof was given
to show that both were SCs. Symmetric divisions have been also observed in SCs in the adult Drosophila
ovary, where SCs can be induced to divide symmetrically and to regenerate an additional SC after experi-
mental removal of one SC from their niche (Morrison and Kimble, 2006). Mammalian adult SCs, that are
supposed to divide asymmetrically under steady-state conditions (Morrison and Kimble, 2006; Januschke
and Gonzalez, 2008), retain the capacity to divide symmetrically to repopulate the SC pool when depleted
by injury or disease (Morrison and Kimble, 2006). Depletion of the SC pool in the sub-ventricular zone
of the mouse forebrain after antimitotic drug infusion induces symmetric neural SC divisions that restore
the SC number (Doetsch et al., 2002). Moreover, the death of rodent forebrain cells in adult rat subjected
to strokes transiently increases the rate of symmetric division among sub-ventricular zone progenitors,
leading to an increase in neurogenesis (Zhang et al., 2004). Finally, in the haematopoietic system, after
chemotherapy-induced depletion of blood cells, SCs expand about ten-fold in number to replenish both
the SC niche and the differentiated cell pools (Wright et al., 2001; Bodine et al., 1996; Morrison et al.,
1997). All these observation suggest that the facultative use of symmetric or asymmetric divisions by
SCs might represent a conserved mechanism, which allows production and maintenance of appropriate
numbers of SCs and differentiated progeny in response to developmental or environmental signals. The
balance between self-renewal and differentiation is therefore strictly regulated to maintain a relatively
small population of long-lived SCs while producing large numbers of differentiated progeny.
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4.3.2 Stem Cell Self-Renewal and Cancer
Recent genetic studies in flies have shown that aberrant regulation of self-renewal and differentiation in
SCs can result in an increase in SC numbers and tissue overgrowth, leading to transplantable tumours
which resemble mammalian cancer (Gonzalez, 2007; Januschke and Gonzalez, 2008; Wodarz and Gonzalez,
2006). The larval neuroblasts in Drosophila divide asymmetrically to generate one new neuroblast and
a small basal GMC. Perturbations, usually loss-of-function, of any of the several proteins that control
asymmetric self-renewing divisions in these cells, including proteins that regulate neuroblast polarity
(lgl, dlg and scrib), asymmetric segregation of GMC-fate determinants (Mira, Numb), the GMC-fate
determinants themselves (Pros, Brat) and mitotic spindle alignment (Pins, Mud) result in the development
of breast tumours(Clarke and Fuller, 2006; Clevers, 2005; Gonzalez, 2007; Januschke and Gonzalez, 2008).
Moreover, mis-segregation or gain of function mutations of the neuroblast fate determinant aPKC leads
to an enormous increase in the number of larval neuroblasts (Lee et al., 2006). Finally, the larval mutants
AurA and Polo also show increased numbers of neuroblasts that develop in malignant tumours after
adult implantation (Januschke and Gonzalez, 2008). These observations convey the existence of a causal
relationship between loss of polarity and/or asymmetric division in the neuroblast and tumourigenesis
in the mutant neuronal tissue. Thus, asymmetric divisions might function as a mechanism of tumour
suppression in the fly neuroblast, and impaired fate specification during SC division might be one of
the initial events that drive these cells into malignancy. In higher organisms this correlation has not
been demonstrated, although several evidences suggest that the intact function of regulatory mechanisms
of self-renewal in SCs is necessary for the propagation of already established cancers in mouse models.
The Polycomb group gene Bmi-1 is involved in the regulation of self-renewal of normal SCs (Lessard
and Sauvageau, 2003; Molofsky et al., 2003; kyung Park et al., 2003; St-Jacques et al., 1998), but it is
also required for the survival and proliferation of AML leukemic SCs (Lessard and Sauvageau, 2003).
Similarly, the correct function of the Hedgehog pathway, which is involved in the regulation of SCs in
various tissues (Ahn and Joyner, 2005; Beachy et al., 2004; Watkins et al., 2003), is also required for the
transplantability of normal haematopoietic SCs and increases the number of leukemogenic SCs in a CML
model (Zhao et al., 2009). Accordingly, inhibition of the Hedgehog pathway in cutaneous basal carcinoma
induces regression of established lesions (Hutchin et al., 2005). Furthermore, it has been shown that the
presence of tumour suppressor p53 is required for the maintenance of a quiescent state in haematopoietic
SCs (Liu et al., 2009; Akala et al., 2008), and restoration of the p53 function in established p53 deficient
tumours results in the regression of the malignancy (Xue et al., 2007; Ventura et al., 2007).
At present it is not clear whether there may be a direct causal relationship between the loss of SC
polarity and/or asymmetric divisions and tumour initiation in humans. The machinery that drives asym-
metry in adult tissue SCs in mammals is largely uncharacterized, and aberrant regulation of self-renewing
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divisions in cancer SCs still needs to be confirmed. Nevertheless, the genes that control asymmetric cell
divisions in flies have a conserved role in the regulation of cell polarity and in tumour suppression in mam-
mals, suggesting that polarity loss may contribute causally to cancer also in higher organisms(Gonzalez,
2007; Januschke and Gonzalez, 2008). Some examples include HUGL-1, the human homologue of Lgl,
which is frequently deleted in cancer and, if inactivated, leads to a loss of polarity and dysplasia in the
central nervous system of mouse models(Grifoni et al., 2004; Klezovitch et al., 2004); Numb, a negative
regulator of the cell-fate determinant Notch, which functions as a tumour suppressor in breast cancers
(Colaluca et al., 2008); the LKB1, VHL and PTEN tumour suppressor proteins, which interact with
components of the PAR–aPKC complex and are frequently mutated in tumours (Baas et al., 2004; Barry
and Krek, 2004; von Stein et al., 2005); NuMA (Nuclear mitotic apparatus protein 1), the human or-
thologue of Mud, which is linked to leukemia (Sukhai et al., 2004) and breast cancer (Kammerer et al.,
2005) susceptibility. An interesting correlation between the expansion of SC pools, cancer development
and, possibly, regulation of SC divisions was recently described in familial adenomatous poliposis (FAP)
colorectal tumours (Boman and Huang, 2008). Altogether, these observations imply that many genes that
are involved in the regulation of SC self-renewal may act in fact as tumour suppressors or may become
oncogenic if altered. Thus, deregulation of the machinery that controls and ensures the correct balance
between symmetric and asymmetric SC divisions may lead to alteration of tissue homeostasis, increase of
the SC pool and, finally, cancer.
Targeting of the machinery that regulates self-renewal in normal and cancer SCs inevitably raises the
question of toxicity that can result from the inhibition of pathways that are shared between normal and
tumour cells. A way to avoid this toxicity is to target mutations that are active only in CSCs. Some of
these have already been identified and include the deletion of the PI-3 kinase pathway regulator Pten,
which results in a mieloproliferative disease that quickly develops into a CSC based leukemia. Interestingly,
deletion of Pten resulted also in the depletion of normal haematopoietic SCs in a cell-autonomous manner,
most likely through mTOR. Rapamycin-mediated inhibition of mTOR induced the eradication of leukemic
SCs and the restoration of the normal SC function (Yilmaz et al., 2006). Similarly, the Wnt/β-catenin
pathway has been shown to sustain the growth of CSCs in chemically induced cutaneous squamous
carcinomas but is not required for tissue homeostasis (Malanchi et al., 2008). These observations confirm
that a good anticancer approach will be selectively targeting mechanisms of tumour propagation.
4.3.3 p53 and Self-Renewal
The tumour suppressor p53 is mutated in 50% of all human cancers; where it is present in its WT form, its
function is often attenuated as a result of the alteration of its regulating pathways (Vousden and Prives,
2005). The activity of p53 in suppressing tumour formation through the induction of cell cycle arrest in
stress situations has been long known, nevertheless, new roles for p53 in other processes like metabolism,
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autophagy and oxidative stress are emerging. p53 is activated in response to cellular stress following
DNA damage, telomere dysfunctions, replication stress, hypoxia, nutrient deprivation and in response to
oncogene activation to limit the propagation of cells under adverse conditions (Kastan and Berkovich,
2007). The expression and activity of p53 is tightly regulated through numerous mechanisms involving
several E3 ubiquitin ligases. In response to stress stimuli p53 is stabilized through the disruption of its
interaction with of one of these ligases, Mdm2, thus preventing its ubiquitination and, consequently, its
degradation(Momand et al., 2000). Once activated, p53 acts as transcription factor, up-regulating a series
of target genes that are involved in various physiological and pathological processes as the inhibition of
cell cycle, induction of apoptosis or senescence, control of genomic stability and inhibition of blood vessel
formation, thus acting as an anti-tumorigenic agent (Vogelstein et al., 2000). In addition to its roles
in tumour suppression, development and aging, newly identified functions for p53 have been described.
Recent evidences suggest that p53 may be involved in the regulation of self-renewal and SC division.
Rambhatla and colleagues have reported that p53 imposed an asymmetric proliferative fate on daughter
cells both in mouse embryo fibroblasts and in one mammary epithelial cell line (Rambhatla et al., 2001)
Accordingly, loss of p53 was found to increase self-renewal of neural SCs in a sphere-forming assay (Piltti
et al., 2006; Meletis et al., 2006), suggesting that p53 can increase the frequency of neural SC symmetric
divisions. In mammary cells, Colaluca and colleagues have shown that the cell fate determinant Numb
mediates the increase in the levels and activity of p53 and the regulation of p53-dependent phenotypes,
through the formation of a Numb-p53-HDM2 ternary complex (Colaluca et al., 2008). Finally, p53 was
shown to negatively regulate the self-renewal of embryonic stem (ES) cells (Lin et al., 2005). Altogether
these findings suggest that the tumour suppressor function of p53 may also require the regulation of self-
renewing divisions. Indeed, recent findings that describe a beneficial effect of the reactivation of p53 in
tumours make this protein a very promising target for anti-cancer interventions.
4.3.4 Myc and Self-Renewal
The Myc family of transcription factors undoubtedly plays an important role in tumorigenesis, as demon-
strated by the fact that although mutations in these genes can be found with low frequency (one every
five tumours), Myc proteins are found to be overexpressed by indirect mechanisms in the majority of
cancers(Laurenti et al., 2009).
Myc genes are required in the developing organism but also play a critical role in adult tissues by
regulating stem and progenitor cells. Extensive evidences show a role for Myc in SC self-renewal in
Drosophila as well as in mammal adult and embryonic SCs. In Drosophila, Myc has been shown to inhibit
differentiation and promote self-renewal in neuroblasts and ovarian germ line SCs(Betschinger et al., 2006).
Similar observations have also come from the study of mammalian SCs. By knocking down the
endogenous c- and N-Myc, Varlakhanova et al. have recently shown that Myc is essential in ES cell
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pluripotency and self-renewal, as well as being required during embryogenesis, as lack of Myc genes
in mice embryos results in early lethality (Varlakhanova et al., 2010). These findings indeed confirm
previous observations that state that Myc enhances iPS cell reprogramming, probably through regulation
of proteins and miRNA that govern general metabolism, the pluripotency cell cycle machinery and self-
renewal. Indeed, it has been described in murine ES cells that Myc is controlled by the LIF/STAT3
pathway, promoting self-renewal and pluripotency. Accordingly, exogenous expression of Myc is sufficient
to sustain pluripotency independently of LIF (Cartwright et al., 2005).
A role for Myc in the regulation of adult SCs in mice models has been described for the epidermis, the
haematopoietic system and neural precursors. Increased levels of c-Myc in the skin results in increased
proliferation and arrests SC differentiation (Watt et al., 2008), and lack of Myc in the mouse epidermis
results in severe skin defects and impaired wound healing, which are accompanied, from a cellular point
of view, by the depletion of the proliferative compartment and premature differentiation (Zanet et al.,
2005).
In the mouse haematopoietic system, Myc has been shown to induce self-renewing divisions in SCs,
probably as an effector upon Notch or HOXB4-mediated growth induction (Satoh et al., 2004). Accord-
ingly, the combined loss of c-Myc and N-Myc results in the depletion of the haematopoietic SC pool,
impaired proliferation and differentiation(Laurenti et al., 2008).
Loss of N-Myc has a similar effect in neural precursors, as it induces increased differentiation (Knoepfler
et al., 2002) . On the contrary, Myc overexpression is able to confer high self-renewing and neurogenic
capacities to late-stage neural SCs. This activity is counteracted by the p19 pathway, as activation of
p19 induces differentiation and loss of p19 increases self-renewal in neural SCs (Nagao et al., 2008). The
activity of Myc in regulating neural SC self-renewal has been shown to act through the activation of
its effector Miz-1 (Kerosuo et al., 2008) and more recently, the same group has identified CIP2A as a
cooperator of Myc in the regulation of self-renewal of neural progenitor cells (Kerosuo et al., 2010).
Interestingly, inactivation of p53 and PTEN in neural SCs also results in increased self-renewing poten-
tial, and promotes maintenance of an undifferentiated state. This is accompanied by the overexpression
of Myc which results in the regulation of numerous genes involved in cell cycle, apoptosis, as well as
in SC self-renewal and differentiation (Zhang et al., 2008). These findings are consistent with previous
observations that describe a role for p53 in the repression of Myc expression, which is achieved by direct
binding of p53 to the Myc promoter (Ho et al., 2005). Furthermore Myc translation and degradation can
be modulated by the downstream effectors of the PTEN/PI3K pathway (Gera et al., 2004; Sears et al.,
2000).
These findings suggest that different regulators of SC fate and behaviour may converge onto the Myc
signalling pathway, thereby modulating SC self-renewal and differentiation; accordingly, deregulation of
these processes may induce the aberrant expression of Myc, thus priming the cells to a pre-transformed
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phenotype. Not surprisingly, N-Myc has been shown to regulate the epigenetic state of 90-95% of the
modifications of histone H3 in the human genome, suggesting that its role is not restricted to that of a
canonical transcription factor (Cotterman et al., 2008).
4.4 Reprogramming of Adult Differentiated Cells
Reprogramming of adult cells into pluripotent cells can be achieved by the expression in adult mammalian
cells of a few embryonic transcription factors. The first observations in this direction came from the
very elegant work of Yamanata and Takahashi in 2003, when they expressed a set of 24 pluripotency-
associated transcription factors in mouse fibroblasts, hoping that their activity would induce the expression
of a dormant drug resistance allele integrated into the ESC-specific locus Fbxo15 (Tokuzawa et al., 2003).
Indeed the expression of these transcription factors induced the formation of colonies with ESC properties,
and the progressive elimination of individual factors taken from this pool led to the reprogramming of
mouse fibroblasts with as little as four genes (c-Myc, Oct3/4, SOX2, Klf4) (Takahashi and Yamanaka,
2006). The expression of these four genes induced the formation of cells that if injected into nude mice,
gave rise to teratomas that were composed by cells with the properties of all three germ layers. However,
although these cells express several markers of pluripotency, some of the key markers of ESCs were only
partially expressed. Subsequently, other works were published that described how the use of different
genes in the reprogramming could yield the generation of iPS cells with closer resemblance to ESCs, and
several groups were even able to generate cells with the ability to form a all-iPS cell mouse upon injection
of these cells into tetraploid blastocysts (Stadtfeld et al., 2010).
In the last years, iPS cells have been also generated from human , rat and rhesus monkey fibrob-
lasts, suggesting that the machinery of pluripotency is evolutionally conserved (reviewed in Stadtfeld and
Hochedlinger, 2010). Furthermore, several groups have demonstrated that not only adult differentiated
fibroblasts have the ability to return to their pluripotent state, but also keratinocytes, neural cells, stom-
ach and liver cells, melanocytes, pancreatic β cells and terminally differentiated lymphocytes, showing
that pluripotency can be universally induced (reviewed in Stadtfeld and Hochedlinger, 2010)
These very innovative findings opened new roads for cell-based treatment of several degenerative
diseases as well as providing a very powerful tool for the study of development and differentiation. In fact,
the possibility of reverting adult differentiated cells into embryonic-like cells that can transdifferentiate
into any adult tissue has amazing clinical implications, boosting the bioengineering field and favouring
the development of patient-specific cell-based therapies. Clinical applications of iPS cells concern not only
their use in the therapy of degenerative diseases, but also their use as potent, patient-specific diagnostic
tools. These cells, in fact, can be used for the tailored study of mechanisms of genetic diseases in the
so called “disease modelling”, and to establish targeted therapeutic strategies (Lee et al., 2009; Raya
et al., 2009). In the field of regenerative medicine, iPS cells represent a very promising tool as the use of
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patient-derived functional cells to damaged tissues eliminates all the possible complications that derive
from donor/host incompatibility. Furthermore, the potential to isolate the patients cells and to correct
possible disease-causing mutations ex vivo by homologous recombination makes them a much stronger tool
than the adult patient SCs, that are notoriously difficult to maintain in culture. Studies in this direction
have been performed in mouse models for the treatment of haematological diseases such as sickle cell
anaemia or hemophilia A. In the former, cells from the skin of adult mice affected by sickle cell anaemia
were isolated and reprogrammed into iPS cells, and the disease-causing mutation was repaired in these
cells by gene targeting. These cells, if transplanted back into the donor mice, were able to produce normal
red blood cells, thus curing the disease(Hanna et al., 2007). Similarly, the transplantation of iPSC-derived
endothelial progenitor cells into mice affected by hemophilia A, resulted in the phenotypic correction of
the disease (Xu et al., 2009).
In the field of degenerative diseases, the study of the processes that are responsible for the disease
progression is limited by the accessibility of the affected tissues and the inability to grow the cells in
culture for the sufficient amount of time. The iPS cell technology has opened new lines of research as it
allows for “disease modelling” in vitro, by deriving adult skin cells from affected patients, reprogramming
them into iPS cells and then differentiating these cells into the cell type of the affected tissue. This method
not only allows for the in vitro manipulation of cells that recapitulate the disease, but, by following the
differentiation and development of mutated cells, it also gives the possibility to understand the early events
that contribute to the progression of that particular disease. iPSC have been generated from patients
affected by Hungtington’s and Parkinson’s disease, ALS, juvenile diabetes, muscolar dystrophy, Fanconi
anaemia, Down syndrome and others, providing potent systems for the study of these diseases (reviewed in
Stadtfeld and Hochedlinger, 2010). Such approaches are being undertaken also in the study of multigenic
diseases like Alzheimer’s disease type I diabetes, although the in vitro modelling of multigenic diseases
may be more difficult than modelling of monogenic ones. Nevertheless, promising results in vitro have
come from the treatment ex vivo of iPSCs derived from patients affected by SMA, familial dysautonomia
(FD), and LEOPARD syndrome with experimental drugs that resulted in the attenuation of the symptoms
(reviewed in Stadtfeld and Hochedlinger, 2010) (Fig. 4.7).
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Figure 4.7: iPS technology and applications.
Cells from adult tissues from patients or mouse models are collected and reprogrammed according to
published protocols. Reprogrammed clones are selected and used for developmental studies or corrected
in vitro for their mutations. Cells are then induced to differentiate into specific adult cells and used for
in vitro studies or to repair the lesions in patients or mouse models.
The iPSC technology has been subject to a very rapid development, but the application of this tech-
nique in the clinic is still far from imminent. Several concerns are slowing the translational process, and
these all revolve around safety issues. In fact, iPSCs are prone to form teratomas, like ESCs, and the
differentiation protocols still do not ensure 100% differentiation efficiency. Furthermore, the generation of
iPSCs proceeds through the integration of vectors that may disrupt endogenous genes, therefore render-
ing it necessary to improve the iPSC generation techniques, with as little alteration of the target cells as
possible. Finally, it has been shown that reprogrammed cells are subject to the accumulation of genomic
alterations that involve the epigenetic imprinting and often result in the maintenance in the reprogrammed
cells of the epigenetic memory of the cell of origin. Indeed, all these fall backs challenge the application
of this technique in human patients, and has led many research groups to analyse in depth the process of
reprogramming from a genetic and an epigenetic point of view, to be able to achieve the creation of cells
with minimal or no genomic alteration.
The discovery of iPSCs has undoubtedly widened the knowledge of the processes of development and
differentiation, and has promising implications in regenerative medicine. In fact it has shown that few
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transcription factors are in charge of maintaining the SC fate and that epigenetic signatures accompany
the differentiation process. Because these mechanisms are often deregulated in cancer, the study of iPSCs
will possibly also help in elucidating the alterations that take place during tumorigenesis.
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5.1 Animal Manipulation
5.1.1 Animal Models
MMTV-ErbB2-transgenic mice were in the FVB background (Muller et al., 1988). P53KO mice were in
the C57/BL6J background (back-crossed in our group starting from a 129sv background). As controls for
these mice we used corresponding WT strains (FVB or C57/BL6J respectively, purchased from Harlan) .
Transgenic mice expressing the green fluorescent protein (GFP) (Okabe et al., 1997) or the Red fluorescent
protein (RFP) (Vintersten et al., 2004) that were used for the mammosphere clonality assay are in the
C57/BL6J background. For serial transplantation experiments we used GFP transgenic mice in a FVB
background. All the experiments with WT mammospheres were carried out in samples derived from FVB
WT mice.
5.1.2 Transplantation Experiments
The sample material to be injected (primary mammary cells, dissociated mammospheres, PKH cell subsets
or intact mammospheres) was collected into sterile Eppendorf tubes and gently pelleted in a benchtop
microfuge. Cell or mammosphere pellets were resuspended in fresh PBS, counted, and resuspended in
PBS at the appropriate cell density (injection volume= 20-30 µl). 3 week-old female singenic mice were
anaesthetised with 2.5% Avertin in PBS (100% avertin: 10 g of tribromoethanol, Sigma, in 10 ml of
tertamyl alcohol, Sigma) and the fat-pad of their 4th mammary gland was depleted of the endogenous
epithelium. At 3 weeks of age the epithelial tree has not undergone the puberty-driven development that
results in the penetration of the fat pad, and can easily be removed by surgical asportation of the area
spanning from the nipple to the lymph node, leaving the fat-pad clear for the injection of exogenous cells
(Fig. 5.1).
3 Weeks Cleared Fat Pad Repopulation
Figure 5.1: Fat pad whole mounts.
Whole mounts of 3-week-old fat pad (left panel), cleared fat pad (central panel) and cleared fat pad 8
weeks after transplantation of primary mammary epithelial cells (right panel). Modified from Smalley
and Ashworth, 2003 (Smalley and Ashworth, 2003).
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For the evaluation of positive outgrowths, the fat pads were collected (8 to 10 weeks after transplanta-
tion), stained with Carmine Alum and analysed as described ((DEOME et al., 1959; Sleeman et al., 2006).
Briefly, fat pads were scored as negative for outgrowths if “no epithelial structures could be observed or if
an epithelial ductal network could be seen, in which the majority of ductal branching had the same direc-
tion and had grown in from one edge of the fat pad”. They were instead scored as positive if “outgrowths
could be seen to have originated from a central region of the cleared fad pad and the directionality of the
ductal branching was different in different parts of the fat pad”. The presence of TEBs in the outgrowths
was also a hallmark of exogenous epithelial growth. For each outgrowth, we calculated the extent of host
fat pad filling, expressed as percentage of penetration. Values of fat filling were heterogeneous among
different outgrowths, and ranged from 25 to 80%.
5.1.3 Statistical Analysis of Positive Transplants
Limiting dilution data and SC frequencies were analysed using generalised linear models, as implemented in
the limdil function of the ‘statmod’ package (http://cran.r-project.org/web/packages/statmod/index.html)
for the R computing environment (http://www.r-project.org/). The single hit Poisson model underling
limiting dilution was estimated by a complementary log-log generalised linear model. A confidence inter-
val was obtained for the SC frequency by computing two-sided 95% Wald confidence intervals. In cases
of zero outgrowths, exact binomial confidence intervals (one-sided 95% Clopper-Pearson) were computed.
Goodness of fit of the single-hit model was estimated by testing, using the likelihood ratio test, the null
hypothesis that the angular coefficient equals to 1 in the linear model fitted with two two-parameters.
The null hypothesis was not rejected (p > 0.05) for any dilution series (Bonnefoix et al., 1996).
5.1.4 Carmine Alum Whole Mount Method
Transplanted mammary glands were stretched out onto slides and fixed overnight in a 1:3 solution of acetic
acid/ethanol. Slides were washed twice in distilled water for 10 minutes and then stained overnight at room
temperature with Carmine Alum solution (0.2% carmine, 0.5% aluminium potassium sulfate in water,
Sigma). Destaining was performed in 70% ethanol for 30 minutes, followed by two 30 minutes washes in
95% and 100% ethanol. Finally, samples were soaked in a 1:2 solution of benzylalcohol/benzylbenzoate
(Sigma) until the fat pads clarified.
5.1.5 Nutlin-3 Treatment in vivo
Nutlin3 was either purchased from Cayman Chemicals or supplied by M.Varasi (Dept. of Chemistry, DAC
s.r.l., Milan, Italy). Two month old MMTV-ErbB2 mice were treated with Nutlin-3 or DMSO for two
weeks (i.p. injection once every two days). Mice were sacrificed either immediately after treatment to
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evaluate the effect o Nutlin-3 on SCs by limiting dilution transplantation, or after two months to evaluate
tumour formation after Nutlin-3 treatment.
5.1.6 Preparation of Paraffin Sections
For the preparation of paraffin-embedded sections: breast tissues freshly collected from mice, or whole-
mounted tissues were fixed overnight with 10% formalin. Matrigel cultures were embedded in 1% low
melting point agarose. The prepared samples were sequentially treated for 1 hour at room temperature
with 70%, 80%, 95% ethanol, three times with 100% ethanol, twice with xylene and twice for two hours
at 58°C with paraffin. The specimens were then embedded in paraffin and sectioned with a microtome
at 2 µm thickness. Slides were stained with haematoxylin-eosin for histological analysis or stained by
immunohistochemistry.
5.1.7 Immunohistochemistry
Paraffin sections were twice deparaffinized with histolemon (Carlo Erba) for 10 minutes and hydrated
through graded alcohol series (100%, 95%, 70%, 50%, 30% ethanol and water) for 5 minutes. Antigen un-
masking was performed with 0.1 mM citrate buffer (pH=6) under microwave irradiation for 10 minutes at
750W followed by incubation with 3% hydrogen peroxide in distilled water for 5 minutes at room tempera-
ture. Slides were subsequently pre-incubated with an antibody mixture (2% BSA, 2% normal goat serum,
0.02% Tween20 in TBS) for 20 minutes at room temperature and then stained with primary antibody
overnight at 4C. After two washes with TBS slides were incubated with a secondary antibody (DAKO
Envision system HRP rabbit or mouse) for 30 minutes at room temperature and washed twice again in
TBS. The sections were subsequently incubated in peroxidase substrate solution (DAB DAKO) for 2 to
5 minutes, rinsed in water, counterstained with haematoxylin for 30 seconds, dehydrated through graded
alcohol series (water and 30%, 50%, 70%, 95%, 100% ethanol) for 5 minutes each and finally mounted with
Eukitt (Kindler GmbH). Primary antibodies used in this work were: rabbit anti-K5 (Covance), mouse
anti-K8 (Progen Biotechnik), rabbit anti-Ki-67 (Novocastra Laboratories), rabbit anti-cleaved caspase-3
(D175, Cell Signalling).
5.2 Cell Culture and Manipulation
5.2.1 Isolation of Mouse Mammary Epithelial Cells
The 2nd, 3rd and 4th mammary glands were collected from 4-12 week-old virgin WT, ErbB2-transgenic
or p53 KO mice. Mammary tissues were mechanically dissected into small pieces with scissors, and en-
zymatically digested with the following digestion mixture: Dulbecco’s modified Eagle’s medium (DMEM,
BioWhittaker), 5% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml strep-
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tomycin, supplemented with 200 U/ml collagenase (Sigma) and 100 U/ml hyaluronidase (Sigma) for 5
hours at 37°C in a humid atmosphere containing 5% CO2. Every 30 minutes, the samples were mixed
by pipetting to facilitate the tissue dissociation. When the digestion was complete, the cell suspensions
were centrifuged at 80xG for 5 minutes to allow precipitation of epithelial cells but not of fibroblasts and
adipose cells(Stingl et al., 1998).The cell suspension was washed in PBS and filtered through 100, 70,
40 and 20 µm meshes to eliminate cell aggregates. The cells were then subjected to osmotic shock with
0.2% NaCl for 2 minutes, followed by a neutralisation step with 1,6% NaCl to lysate red blood cells. The
remaining epithelial cells were plated to obtain mammospheres, stained with the PKH26 fluorescent dye
or used in transplantation assays.
5.2.2 Mammosphere Culture
Primary mammary cells were plated onto ultralow attachment plates (Falcon) at a density of 100,000 viable
cell/ml (to obtain primary mammospheres) in a serum-free mammary epithelial basal medium (MEBM,
BioWhittaker), supplemented with 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin,
5 µg/ml insulin, 0.5 µg/ml hydrocortisone, 2% B27 (Invitrogen), 20 ng/ml EGF and bFGF (BD Bio-
sciences), and 4 µg/ml heparin (Sigma) and cultured at 37° C in a humid atmosphere containing 5% CO2
(standard culture). In these conditions mammary epithelial cells grow as spherical clonal colonies called
mammospheres(Dontu et al., 2003; Liao et al., 2007) that reach their maximum size in 5-6 days. After 7
days of culture, primary mammospheres (obtained from freshly isolated mammary cells) were dissociated
mechanically using a fired-polished pipette and re-plated to obtain secondary mammospheres at a density
of 20,000 cells/ml in 6-well low-adhesion plates. The same procedure was repeated at each passage.
5.2.3 Mammosphere Growth Curves
For the measurement of mammosphere growth curves, 5,000 cells from primary dissociated mammospheres
were plated in quadruplicate onto ultralow attachment plates (24 multiwell) at each passage. After 6 days,
the newly formed mammospheres were counted and subsequently collected and manually dissociated by
pipetting. At each passage, the number of retrieved mammospheres reflects the number of mammosphere-
initiating cells present in the original culture and the number of cells counted after dissociation allows
for the evaluation of the number of cells per sphere that were formed. The average number of cells that
compose a sphere (sphere size) was calculated as the ratio between the number of cells and the number
of spheres at each passage. Cumulative sphere and cell curves were calculated based on the ratio between
plated spheres and obtained spheres and cells respectively. Since the mammosphere size was constant over
the several passages (Cicalese et al., 2009), the number of plated mammospheres was calculated as 5,000
divided by the average size of the mammospheres over the passages. The cumulative curves plotted in a
semi-logarithmic graph appear as straight lines, thus suggesting they approximate an exponential curve,
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as expected for a cell population that grow or die with a constant rate during the time. Growth rates
(G.R.) were evaluated as the slope of the trendline of the exponential curves. To verify the exponential
correlation between the cumulative numbers and time of culture, exponential regression of the data was
performed. The coefficients of determination (R2) showed values near to 1 in each of the measured curve,
thus indicating the goodness of the fitting model.
5.2.4 PKH26 Assay
The PKH26 staining was performed with a slight modification to the described protocol (Sigma, PKH26-
GL). Primary mammary cells were washed and resuspended in PBS at the concentration of 10 million
cells/ml, and stained for 5 minutes at room temperature by adding an equal volume of a 2x PKH26
mix (1:250 PKH-26 dye in PBS). The reaction was blocked for 1 minute by adding an equal volume
of 1% bovine serum albumin (BSA) in PBS. The cells were then washed twice with culture medium
and plated to obtain primary mammospheres. FACS sorting was performed on single cell suspensions
from secondary mammospheres using a FACS Vantage SE flow cytometer (Becton&Dickinson) equipped
with a 488 nm laser (Enterprise Coherent) and with a band pass 575/26 nm optical filter for PKH-26
fluorescence detection. An average sorting rate of 1,000 events per second at a sorting pressure of 20 PSI
was maintained. Cells were first sorted to separate PKHhigh and PKHlow+neg cells. The PKHhigh region
was defined according to the estimated percentage of SCs in mammospheres. A second round of cell sorting
was then performed to separate PKHlow from PKHneg cells. The PKHneg gate was selected according to
the basal fluorescence of unstained cells. The boundary regions were excluded to minimise potential cross
contamination due to Gaussian spreading of intensity curves. The obtained PKH-subsets were cultured
as mammospheres, plated in methylcellulose for time-lapse experiments or used in transplantation assays.
5.2.5 Time-Lapse Analysis
Methylcellulose (MethoCult® SF M3236) was reconstituted with 20% mammosphere medium containing
5x concentrated supplements. 500-1,000 PKHhigh cells were re-suspended in Methyl Cellulose in complete
medium, plated in glass bottom dishes (MatTek Corporation, US) and incubated in a humid atmosphere
containing 5% CO2 at 37°C over night to allow the cells to sediment. Time-lapse video microscopy was
performed with a Scan^R screening station (Olympus-SIS, Munich, Germany) equipped with a microscope
incubation chamber (Evotec, Germany). Cells were observed through a 10x 0.4 NA objective. Both DIC
(differential interference contrast) and PKH red fluorescence images were collected with auto focusing
procedures and compensated for focal shift. Different focal planes were recorded to prevent loss of image
contrast due to axial cell movement inside the well. Images were captured every hour for 7 days, starting
14 hours after plating, and reconstructed using the ImageJ software.
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5.2.6 Matrigel Culture
Single cells deriving from dissociated primary mammospheres were matrigel-embedded. About 1,000 cells
were re-suspended in 500 µl of Matrigel Matrix (BD Bioscience) and plated in a 12 well plate. After 30
minutes at 37 °C, 1 ml of differentiation medium (DMEM: F12 1:1, 2% FBS, 10 ng/ml EGF, 5 µg/ml
insulin, 100 U/ml penicillin and 100 µg/ml streptomycin) was layered on the Matrigel and then changed
every three days. After 3 weeks the formed structures were analysed under an inverted microscope and
embedded in paraffin.
5.2.7 Lentiviral Infection
293-T packaging cells, an immortalised cell line from human fetal kidney fibroblast, were cultured in a
humid atmosphere containing 5% CO2 in DMEM supplemented with 10% FBS, 2 mM glutamine, 100
U/ml penicillin and 100 µg/ml streptomycin. For lentiviral production 293-T cells were transfected with
the calcium-phosphate procedure with a mixture of 4 DNAs: 2,5 µg of pRSV (Rev), 5 µg of pMDL
(gag&pol), 3 µg of pENV (VSV-G), and 10 µg of the lentiviral vector per plate. 62.5 µl of 2M CaCl2
were added to the DNA mix and brought to a total volume of 500 µl with water. The mix was added
drop-wise to 500 µl of 2X HBS (HEPES buffered saline: 250mM HEPES pH 7.0, 250mM NaCl and
150mM Na2HPO4). After 15 minutes of incubation, the precipitate was distributed on 60-70% confluent
exponentially growing cells. The medium was replaced 12 hours later with fresh medium and 36 hours later
with mammosphere medium. Viral supernatant was collected after 24 hours and filtered through a 0.45
µm syringe-filter. Cells from dissociated primary mammospheres were resuspended in viral supernatants
to a final concentration of 50,000 cell/ml and subjected to three cycles of infection in suspension (6h, o/n,
6h). After the third infection cycle, the cells were resuspended in fresh mammosphere medium to obtain
secondary mammospheres.
For this study we utilised the following lentiviral vectors:
• pLKO-Numb (and its control pLKO): a vector expressing short hairpin RNAs directed against Numb
and the cassette for the puromycin resistance.
• pSico-p53sh (and its control pSICO): a vector expressing short hairpin RNAs directed against p53.
• pWPI-p53 (and its control pWPI): a vector carrying the human p53 cDNA under the control of the
CMV promoter.
• pWPI-MycER (and its control pWPI): created from the pWPI backbone and the insertion of the
MycER sequence Littlewood et al. (1995).
• pRDI-Myc (and its control pRDI): a vector carrying the human c-Myc sequence under the control
of the CMV promoter
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• pTWEEN-Omomyc (and its control pTWEEN): a vector carrying the Omomyc sequence under the
control of the CMV promoter
• pLL3.7-mMyc (and its control pLL3.7): a vector expressing short hairpin RNAs directed against
mouse c-Myc and the cassette for the puromycin resistance.
5.2.8 Human Mammary Epithelial Cell Isolation
Human samples of normal mammary glands were retrieved from reduction mammoplasties performed at
IEO, Milan, Italy. Tissues were processed as described (Dontu et al., 2003; Pece et al., 2010) to isolate
mammary epithelial cells. Human mammospheres were infected with lentiviral vectors using the same
protocol previously set up for murine mammospheres.
5.3 Protein Expression Analysis
5.3.1 RT-PCR and PCR
Total RNA from mammospheres was isolated using the PicoPureRNeasy isolation Kit (Arcturus) and
reverse transcribed using random hexamers (Roche Diagnostics), according to the manufacturer protocols.
Real-time RT-PCR analyses were done in triplicate on the Applied Biosystems 7500 Fast Real-Time PCR
System with the SYBR Green PCR kit as instructed by the manufacturer (Applied Biosystems). The
amount of c-Myc mRNA was normalised to the amount of 18S rRNA.
5.3.2 Immunofluorescence
Cells from dissociated mammospheres were fixed in suspension with 4% paraformaldehyde for 10 minutes,
washed three times in PBS and plated onto polilysinated coverslips. Cells were then permeabilized 5
minutes with 0.1% Triton-X100 in PBS at room temperature, washed three times in PBS and blocked
with 3% BSA in PBS (blocking solution) for 20 minutes. Staining with primary antibodies was performed
in a humid chamber for 1 hour at room temperature and followed by three washes in PBS. Coverslips
were then stained with secondary antibodies for 30 minutes at room temperature, washed three times in
PBS, counterstained with DAPI and mounted in mowiol. Samples were analysed under an AX-70 Provis
(Olympus) fluorescence microscope equipped with a b/w cooled CCD camera (Hamamatsu c5985). In this
work we used a rabbit monoclonal c-Myc antibody (1:800 in blocking solution, D84C12 Cell Signalling)
followed by an anti-rabbit Cy5 antibody (1:100 in blocking solution, Jackson Laboratories).
5.3.3 Intracellular Localisation of Numb
To detect endogenous Numb, FACS-sorted PKHhigh cells were cultured in suspension for 36 hours in the
presence of 25 µM Blebbistatin. Immunofluorescence was performed as described in section 2.5 using an
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anti-Numb antibody (Colaluca et al., 2008) followed by an anti-mouse Alexa 647 antibody (30 minutes at
room temperature, 1:100 in blocking solution, Jackson Laboratories) . Confocal analysis was performed
with a Leica TCS SP2 AOBS confocal microscope. For each cells 15-20 adjacent 0.5µm optical sections
were collected.
5.3.4 Western Blot Analysis
10,000 to 20,000 cells from dissociated mammosphere were collected, washed in PBS and lysed in 50 µl of
Laemmli sample buffer (62.5 mM Tris-HCl pH 6.8%, 2% SDS, 5% 2-mercaptoethanol and 10% glycerol).
SDS-PAGE was performed in a BIORAD apparatus using a SDS running buffer (0.025 M tris-base pH
8.8; 0.192 M glycine; 0.1% SDS). Following SDS-PAGE electrophoresis, proteins were transferred to
nitrocellulose membranes (Protan; Schleicher & Schuell) by electroblotting for 16 hours at 30V. Membranes
were stained with Ponceau S to verify the efficiency of the transfer. Membranes were blocked in blocking
solution (5% low fat milk in TBS-T: Tris Buffered Saline, 0.1% Tween 20) for 1 hour and then incubated
with the primary antibody in blocking solution for 1 hour at room temperature or 12 hours at 4°C.
The membranes were washed three times in TBS-T (10 minutes each) and incubated with a secondary
antibody linked to horse-radish peroxidase for 1 hour at room temperature. After three 15-minute washes
in TBS-T, the proteins were visualised using enhanced chemiluminescence (ECL, Amersham), according
to manufacturer’s instructions, followed by autoradiography. The following antibodies were used in this
work: mouse monoclonal anti-vinculin (1:1000 in blocking solution, Sigma), rabbit polyclonal anti-ph18p53
(1:1000 in blocking solution, calbiochem), mouse monoclonal anti-p53 (1:1000 in blocking solution, clone
AI25, gift from K. Helin), mouse monoclonal anti-p21 (1:300 in blocking solution, clone F5, Santa Cruz),
rabbit polyclonal anti-cleaved caspase3 (1:500 in blocking solution, clone D175, Cell Signalling), rabbit
polyclonal anti-p16 (M156 Santa Cruz).
For Myc immunoprecipitation, lysates from 4 million cells for each sample were incubated with pro-
tein A resin and mouse monoclonal antibody against c-Myc (C-33, Santa Cruz) for 4 hours. Immuno-
precipitated material was loaded onto an SDS-PAGE gel and subsequently blotted onto a nitrocellulose
membrane. Myc was visualised with a rabbit polyclonal anti c-Myc antibody (1:1000 in blocking solution,
gift of S. Hann, Vanderbilt University School of Medicine, Nashville, TN). Normalisation was evaluated
by the expression of vinculin.
5.4 Comparative Genomic Hybridisation Analysis
Genomic DNA was prepared using the Qiagen Genomic DNA kit (Genomic tip 100/G), according to the
instructions supplied by the manufacturer. DNA from non-infected cells was labeled with Cy5, whereas
DNA from the reprogrammed clones was labeled with Cy3. Equal amounts of Cy5- and Cy3-labeled DNA
were hybridised against high- density tiling microarrays containing probes mapping to mouse chromosomes
32
5.4 Comparative Genomic Hybridisation Analysis 5 MATERIAL AND METHODS
9-14 (Roche Nimblegen array MM8 WG CGH3; Build 36). The median probe density on the arrays was
1,388 bp. The data were analysed using the software provided by the manufacturer.
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6.1 Characterisation of Normal and Tumor Mouse Mammary Stem Cells
The cancer stem cell hypothesis is constantly being supported by new emerging data, and it is gaining
more and more consent with time. In light of this, the need to study the mechanisms that regulate
the behaviour of normal and tumour SCs requires these cells to be isolated, cultured and maintained in
vitro in their multipotent state. This is why, in recent years, there have been several attempts at the
isolation and culture of normal and tumour SCs and these have conveyed to the establishment of culturing
conditions for SCs of various organs including bone marrow, brain, breast, gut and skin and of several
tumour tissues. Based on recently published protocols (Dontu et al., 2003; Liao et al., 2007), we set-up
culturing conditions for the in vitro propagation of mouse mammary SCs and CSCs. These protocols rely
on the ability of these cells to grow in suspension, in a serum-free medium supplemented with EGF and
FGF, as spheroids called mammospheres (Fig. 6.1).
Mammary Gland
Chopping and Digestion
Tissue Collection
Centrifugation 
and 
Serial Filtration Plating in Suspension
Figure 6.1: Schematic representation of the isolation and characterisation of mouse mammary
SCs.
Tissues are collected from the mice, mechanically dissected and subjected to enzymatic digestion. The
samples are then centrifuged to remove the stroma and run through serial passages of filtration to eliminate
undigested clusters. The purified cell suspension that is obtained is then plated in suspension, in the
absence of serum and in the presence of growth factors, to allow epithelial SCs to form mammospheres.
As tumour model, we have used a transgenic mouse carrying a constitutively active form of the ErbB2
oncogene (with the activating mutation Val664 to Glu664) under the control of the Mouse Mammary
Tumour Virus (MMTV) promoter (Muller et al., 1988). ErbB2 is mutated or overexpressed in 20-30%
of breast cancer cases, and it has been recently demonstrated that the tumours that are formed in the
MMTV-ErbB2 mouse follow a CSC model (Grange et al., 2008).
We have characterised the mammospheres that are formed by culturing epithelial cells isolated from
normal mammary glands or tumour biopsies and we have shown that these mammospheres i) are clonal
in origin (Fig. 6.2), ii) they can be serially passaged (Fig. 6.3) , iii) they are able to form complex
threedimensional structures if cultured in semisolid media in vitro (Fig. 6.4), and iv) they can reform
tissues with the same complexity of their tissue of origin if transplanted into the cleared fat-pad of
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singenic recipient mice (Fig. 6.5). The transplantation of mammary epithelial cells into the fat-pad of
a recipient mouse is a standard technique to study the regenerative potential of cells. At 3 weeks the
mammary epithelium of the inguinal mammary gland is still concentrated in the nipple area and has not
penetrated the fat pad. After surgical removal of the endogenous epithelium, the cells are inoculated in
their physiological environment and allowed to develop (DEOME et al., 1959).
Bright Field Fluorescence Merge
Figure 6.2: Mammospheres are clonal in origin.
Mammary epithelial cells were isolated from transgenic mice carrying either the GFP or the RFP proteins,
mixed in equal amounts and plated to form mammospheres. After one week in culture, the clonality of
the formed spheres was assessed by evaluating under a fluorescence microscope the content of GFP- or
RFP-expressing cells in each mammosphere. All the observed mammospheres were composed entirely by
GFP- or RFP-positive cells, confirming that they were clonal and derived from the division of a single
cell. Scale bars as reported.
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Figure 6.3: Mammospheres can be serially passaged.
WT and tumour primary mammospheres can be collected and mechanically disaggregated by pipetting.
If the resulting cell suspensions are replated, secondary mammospheres are formed and the process can
be repeated for several passages, showing that they contain cells endowed with self-renewing abilities.
Figures show representative images of mammospheres formed by WT mammary epithelial cells or tumour
cells. Scales as reported.
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Figure 6.4: WT and tumour mammospheres differentiate and form threedimentional struc-
tures in Matrigel.
Primary WT and tumour mammospheres were disaggregated and plated at clonogenic densities in 3D
Matrigel cultures. Under these conditions, WT cells formed acinus-like structures and occasionally
(<1%) branched/ductal-acinar structures. Single cells from dissociated tumour mammospheres formed
branched/ductal-acinar structures, which were disorganised and frequently lacked lumens, as has been re-
ported for human primary mammary cancer samples (Farnie et al., 2007). Images show transmitted light
(Bright Field) and Hematoxilin/Eosin staining of sections of the paraffin-embedded structures (H&E).
Scale bars as reported.
36
6.1 Characterisation of Normal and Tumor Mouse Mammary Stem Cells 6 RESULTS
WT MMTV-ErbB2
3 Week-Old Mouse
Clearing of the
Fat Pad
Cell Injection
Figure 6.5: Mammospheres form tissues upon transplantation in vivo.
Cells from primary normal or tumour mammospheres were transplanted into the cleared fat-pad of 3-week
old recipient mice as reported (DEOME et al., 1959). The resulting outgrowths were evaluated after 8-
10 weeks by whole mount staining for normal mammary glands, and paraffin-embedding and sectioning
for tumours. Images show: i) Left panel: whole mount staining of a positive outgrowth resulting from
the injection of cells deriving from WT mammospheres; immunohistochemical analysis of basal epithelial
marker K5 and luminal epithelial marker K8 in the same positive epithelial outgrowth. ii) Right panel:
Hematoxylin&Eosin staining of a paraffin-embedded and sectioned tumour arising from the injection of
tumour mammospheres in a recipient mouse. Scale bars as reported.
Altogether, these observations suggest that mammospheres derive from the clonal expansion of cells
endowed with self-renewing and differentiating potential, two properties that define SCs. Serial trans-
plantation experiments confirmed that these cells are indeed true SCs (Fig. 6.6).
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Figure 6.6: Serial transplantation of positive outgrowths
Serial transplantation of mammary epithelial cells derived from a transgenic GFP mouse. Primary trans-
plant (left panels) and secondary transplants (right panels) are shown. Scale bars as reported.
Not all cells that form mammospheres possess stem-like properties, suggesting that these structures
have an intrinsic hierarchic organisation. To investigate the content in SCs of normal and tumour mam-
mospheres, we performed limiting dilution transplantations of cell suspensions derived from disaggregated
normal or tumour mammospheres, into the cleared fat-pads of singeneic mice. The results of these exper-
iments are summarised in Table 6.1 and show that whereas WT cell suspensions contain approximately
1 SC every 300 cells, in tumour cell suspensions, the frequency is increased by three-fold (1 CSC ev-
ery 100 cells). We calculated the mammosphere sizes to be around 360 cells (362±14; n=15) in normal
mammospheres and 520 (522±14; n=13) cells in tumour mammospheres, which predict that each WT
mammosphere contains 1 SC, whereas tumour mammospheres contain approximately 5 CSCs per sphere.
These assumptions were also confirmed for WT samples by limiting dilution transplantation of whole
mammospheres, that yielded a frequency of one positive transplantation every single mammosphere in-
jected (Table 6.1).
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Cell Injection
WT Mammosphere Injection
Table 6.1: Summary of limiting dilution transplantation experiments performed with single
cell suspensions or whole mammospheres.
Upper table: cell suspensions from WT or tumour secondary mammospheres were inoculated in recipient
mice in limiting dilution conditions (from 10,000 to 10 cells). Results show the number of positive
outgrowths evaluated as normal mammary epithelium (WT samples) or tumours (tumour samples) that
arose 8-10 weeks after injection. SC frequencies (Estimates and upper/lower limits) were calculated by
limiting dilution analysis, as described in Material and Methods. Fitting to single hit model is indicated
by p-values > 0,05 (Fit). The significance of the difference in SC frequencies is indicated by p-values <
0,05 (Difference).
Lower table: intact WT mammospheres were injected into recipient mice. Results show positive out-
growths. SC frequencies (Estimates and upper/lower limits) were calculated by limiting dilution analysis,
fitting to single hit model is indicated by p-values > 0,05 (Fit).
Interestingly, the limiting dilution transplantation of freshly isolated cells from normal mammary
tissues or ErbB2-driven tumours showed that in primary uncultured tissues as well, the number of SCs is
increased in tumours compared to normal samples (Table 6.2).
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Freshly Isolated Cells Injection
Table 6.2: Limiting dilution transplantation of freshly isolated cells from normal and tumour
tissues.
Freshly isolated cell suspensions from WT or tumour tissues were inoculated in recipient mice in limiting
dilution conditions (from 10,000 to 10 cells). Results show the number of positive outgrowths evaluated
as normal mammary epithelium (WT samples) or tumours (tumour samples) that arose 8-10 weeks after
injection. SC frequencies (Estimates and upper/lower limits) were calculated by limiting dilution analysis,
as described in Material and Methods. Fitting to single hit model is indicated by p-values > 0,05 (Fit).
The significance of the difference in SC frequencies is indicated by p-values < 0,05 (Difference).
The calculated frequencies of SCs in normal and tumour tissues were around 1:30,000 and 1:4,000
respectively. Altogether these experiments show that in tumour mammospheres and tumour tissues, the
number of SCs is markedly increased compared to the WT counterparts.
6.1.1 Analysis of the Growth Properties of Normal and Cancer SCs
The observation that the number of SCs that can be found in tumour samples is increased compared to
normal samples both in vivo and in vitro, suggested that these cells may possess increased self-renewing
potential. However, the mammosphere system does not allow for a conventional characterisation of the
proliferative potential of SCs, due to their low representation in the bulk of cells that are found in
mammosphere cultures. To circumvent this problem, we analysed the replicative history of normal and
tumour SCs by staining them with a vital fluorescent membrane dye (PKH26) that is equally distributed
between the two daughter cells at each cell division, thus enabling the correlation between the intensity
of the staining and the replicative history of each cell (Lanzkron et al., 1999). Freshly isolated cells were
stained with the PKH26 dye and cultured as mammosphere for two passages. Tertiary mammospheres
were then disaggregated and cell suspensions were separated by FACS sorting into a subpopulation of
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intensely-stained PKHhigh cells (slowly dividing), an intermediate PKHlow subpopulation of cells (rapidly
dividing) and a subpopulation of unstained PKHneg (very rapidly dividing) cells (Fig. 6.7).
SC
SC
SC
Figure 6.7: FACS analysis of cell suspensions deriving from disaggregated tertiary WT mam-
mospheres stained with the PKH26 dye.
FACS plot of the distribution of cells from WT mammospheres according to the intensity of their staining
with the PKH26 dye. In a first round of sorting, the PKHhighpopulation is isolated from the bulk. Subse-
quently, an intermediate and negative populations are separated. On the right, a graphic representation
of the PKH26 dye dilution according to the proliferative history of the cells.
The PKHhighcells were defined as the 0.5-1 % of the total population, based on the estimated fraction
of SCs in the mammosphere cell cultures (0.3% in WT mammospheres and 1% in tumour mammospheres).
The gating for the sorting of PKHnegcells was defined based on the fluorescence intensity of unstained
cells.
Replating of the three PKH populations in normal and tumour samples revealed that only the
PKHhighpopulation in normal samples was able to form mammospheres in vitro, whereas cells with the
ability to form mammospheres could be found in all three PKH populations in tumour samples, suggesting
that, as expected, CSCs are actively proliferating and normal SCs remain quiescent (Fig. 6.8).
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Figure 6.8: Replating of the 3 PKH populations.
Only PKHhighcells from WT samples are able to form mammospheres in vitro, whereas the intermediate
populations ony form small aggregates that cannot be passaged further. On the contrary, tumour mammo-
spheres can arise from all three PKH populations, suggesting that CSCs are actively proliferating. Figures
show representative images of mammospheres formed after the replating of sorted PKH-populations. Scale
bar as represented.
Accordingly, the injection of the WT populations in the cleared fat-pad of singeneic mice resulted in
the formation of positive outgrowths only with the PKHhighpopulation, with as little as a single cell in 10
out of 26 cases. Indeed, this population was highly enriched in SCs, and we could estimate the frequency
of SCs to be approximately 1:3. On the contrary, the injection of the PKHlowand PKHnegpopulations did
not result in the formation of a mammary tissue even at high numbers (up to 100,000 cells).
In line with the data generated in vitro, all three the tumour PKH populations were able to generate
mammary tumours if injected in vivo, although the frequency of tumour initiating cells was progressively
lower in the intermediate- and negatively-stained populations compared to the brightly stained cell fraction
(Table 6.3).
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MMTV-ErbB2
WT
Table 6.3: Limiting dilution transplantation of PKH-sorted cells.
PKH26 subpopulations from WT (upper table) or tumour (lower table) mammospheres were injected
into the cleared fat pads of syngeneic mice (number of injected cells as indicated). Results are shown as
number of outgrowths or tumours per number of injections. SC frequencies (estimates and upper - lower
limits) were calculated by limiting dilution analysis, as described in Material and Methods. Fitting to
single hit model is indicated by p-values >0.05 (Fit). Differences in SC frequencies are calculated for each
sample against the PKH high cell subset. Their significance is indicated by p-values <0.05 (Difference).
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Altogether, these data show that in WT samples SCs undergo limited self-renewing divisions and
can be isolated to near purity based on their replicative history. Contrarily, CSCs possess increased
proliferative potential and undergo several rounds of self-renewing divisions in vitro.
6.1.2 Tumour SCs Divide Mainly Symmetrically
The increased self-renewing potential in CSCs cannot necessarily be correlated with the observed expansion
in the number of CSCs in tumour mammospheres and tumour tissues compared to WT samples. In
normal conditions SCs are maintained in a constant number by self-renewing divisions that result in the
formation of one SC and one progenitor cell that will continue to proliferate and differentiate; in this
scenario, several rounds of divisions result in the maintenance of the SC pool. However, it has been shown
that, during development and injury, SCs can undergo a symmetric type of division that generates two
identical daughter cells endowed with SC properties, thus expanding the SC pool (Noctor et al., 2004;
Wright et al., 2001; Zhang et al., 2004; Lechler and Fuchs, 2005; Morrison et al., 1995)(Fig. 6.9)
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Asymmetric Stem Cell Division
Symmetric Stem Cell Division
Figure 6.9: Schematic representation of the two types of SC division.
Asymmetric SC divisions result in the formation of two daughter cells of which one remains quiescent (SC)
and one carries on proliferating (Progenitor). Symmetric SC divisions expand the SC pool by generating
two functionally identical cells endowed with stem properties.
To investigate whether this process could explain the observed increase in the number of CSCs com-
pared to WT samples, we performed live time-lapse imaging of the first SC divisions during mammosphere
formation, with a protocol that has been already described for the hematopoietic system (Huang et al.,
1999). Briefly, purified PKHhighpopulations from WT and tumour mammospheres were plated in metil-
cellulose media, monitored every hour over a period of 4 days and images were collected at each timepoint.
The reconstruction of the image sequence for each dividing cell allowed us to discriminate symmetrically
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or asymmetrically dividing cells depending on the replicative fate of the two daughter cells. Cell divi-
sions that yielded two daughter cells with the same replicative fate were defined symmetric; cell divisions
that yielded two daughter cells of which one remained quiescent and the other carried on dividing were
considered asymmetric.
Following this approach we were able to determine that 80% of SCs in WT samples adopts an asym-
metric mode of division (n=103) and in much lower frequencies, a symmetric mode of division (7.8%).
In tumour samples CSCs mainly divided symmetrically (80%, n=156), while only 10% of cells divided
asymmetrically (Fig. 6.10).
Symmetric
Ambiguous
Asymmetric
Figure 6.10: Time-lapse imaging of the first cell divisions of a forming mammosphere.
Time-lapse microscopy images of the cell divisions during mammosphere formation. Elapsed time after
seeding is shown at each division event. Pie charts show the frequencies of different types of divisions.
Scale bars are reported.
To corroborate these observations from a molecular point of view, we decided to analyse the pattern
of expression of the fate determinant Numb in dividing SCs by immunofluorescence staining. It’s been
shown that Numb is required for asymmetric cell divisions in Drosophila neuroblasts (Knoblich, 1997;
Caussinus and Gonzalez, 2005) and its asymmetric distribution is critical for mouse cerebral cortical SC
and neuroblast asymmetric divisions (Shen et al., 2002). Similarly, asymmetric segregation of Numb in
cultured satellite muscle cells promotes myogenic differentiation of one of the daughter cells (Shinin et al.,
2006; Conboy and Rando, 2002). The specificity of the anti-Numb antibody was verified by immunoflu-
orescence staining for Numb in cells infected with puromycin-selectable control (pLKO) or Numb-RNAi
(pLKO-Numb) vectors (Fig. 6.11).
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Figure 6.11: Numb RNAi in WT cells.
The specificity of the anti-Numb antibody (a monoclonal antibody, Ab21, generated against amino acids
537–551 of human Numb) was verified by staining RNA-interfered cells and control cells. Wide-field and
confocal microscopy analysis of the infected cells showed punctuate staining of the anti-Numb antibody
at both the cell membrane and the cytosol of all cells, consistently with previously reported localisation
of Numb in mammalian cells at the cortical membrane and within intracellular vesicles (Dho et al.,
2006; Nishimura et al., 2003; Santolini et al., 2000; Smith et al., 2004). In the short hairpin RNA-
infected cells, the anti-Numb staining was markedly reduced in intensity and only detectable in the cytosol,
confirming that the observed anti-Numb membrane staining reflects a specific localisation pattern of Numb
in mammosphere cell suspensions.
To visualise the partitioning of Numb during the first division of normal and tumour SCs, we isolated
the PKHhighpopulation of cells from WT and tumour mammospheres and plated them for 36 hours in
the presence of 25 μM Blebbistatin, a small molecule that blocks the cell division by arresting the furrow
ingression, without interfering with mitosis (Straight et al., 2003). The cells were then fixed and stained
by immunofluorescence for Numb and analysed in confocal microscopy.
The confocal analysis of the distribution of Numb in dividing SCs from WT and tumour mammo-
spheres supported our previous observations from the time-lapse experiments, and showed an asymmetric
localisation of Numb along the membrane of the majority of WT SCs, and a symmetric distribution on
the membrane of dividing CSCs (Fig. 6.12).
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Figure 6.12: Distribution of fate-determinant Numb in WT and tumour SCs.
Confocal analysis of the distribution of Numb on the cell membrane of dividing SCs from WT or tumour
samples. DIC, Numb and DAPI staining and merged channels (Merge) of a representative cell are shown
for each sample. In ~60% (n=82) of WT PKHhigh cells, the anti-Numb staining was weakly cytoplasmic
and formed a clear crescent at the cell membrane, while in ~25% of the cases Numb was uniformly
localised around the cell cortex. In the remaining cells, the distribution of Numb was ambiguous. Confocal
immunofluorescence analysis of Numb localisation in blebbistatin-treated ErbB2 PKHhigh cells revealed
a uniform distribution of Numb around the cortex in the majority of the analysed cells (74.5%; n=47),
with only 14.9% of cells showing polarised localisation.
Relative frequencies of asymmetric and symmetric divisions are shown in the pie charts. Ambiguous:
Numb distribution not consistent among different confocal sections. Scale bar as reported.
Altogether these findings suggest that symmetric and asymmetric divisions coexist in both WT and
tumour SCs, but with opposite relative proportions: WT SCs mainly divide asymmetrically, while tumour
SCs divide symmetrically.
6.1.3 CSCs Possess Increased Self-renewing Properties
To investigate the replicative potential (measured as self-renewing ability and lifespan in vitro) of CSCs
compared to WT SCs, we cultured these cells as mammospheres for several passages. As the behaviour
of SCs in culture is reflected in their ability to form mammospheres, we set up a method to measure a
growth curve that would take into account the fluctuation of both the number of cells and the number of
spheres over passage. At each passage, 5000 cells were plated in quadruplicate in 24-well plates to form
mammospheres, and after one week in culture, the number of formed spheres was counted. These spheres
were then collected and disaggregated, and the number of cells was counted to estimate the mammosphere
size. The data was then arranged into cumulative growth curves that show the variation in the number
of mammospheres and cells during passages. As shown in Fig. 6.13, WT mammospheres progressively
decrease in number and exhaust in culture after 6-7 passages and can not be further cultured, suggesting
that WT SCs have limited lifespan and self-renewing potential. Interestingly, normal tissues can be
serially transplanted only up to 6-7 times (Daniel et al., 1968), confirming our in vitro observations. On
the contrary and in line with the observation that CSCs divide symmetrically, tumour mammospheres
expanded in number over the passages, and showed a near immortal behaviour (up to 36 passages in
selected experiments).
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Figure 6.13: Growth curves of WT and MMTV-ErbB2 mammospheres.
Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right panel) Numbers
were obtained from serial replating of WT (black lines) and tumour (red lines, MMTV-ErbB2) mammo-
spheres. Regression analysis of the data set was performed to obtain trend lines (light lines) that best
approximate the curves. The growth rates (GR) and the coefficients of determination (R2) for each trend
line are reported inside the graph.
Both in the case of WT and ErbB2-tumour mammospheres the cumulative mammosphere number
approximated an exponential curve (R2= 0.99 and 0.98 respectively, Fig. 6.13) indicating that the growth
rate was constant at each passage. However, WT mammosphere growth curve showed a slope of ~0.3,
indicating that SCs decrease by 70% at each passage, whereas the slope of the tumour exponential curve
was ~5, indicating a constant expansion of the number of mammospheres of ~5-fold at every passage.
Together, these findings demonstrate that WT SCs rapidly lose self-renewal potential in culture, while
tumour SCs are nearly immortal, and suggest that these different behaviours reflect intrinsic properties
of WT and tumour SCs, which are not influenced by the time in culture. Furthermore, these data
suggest that the two observed properties of tumour SCs, i.e. extended replicative-potential and increased
frequency of symmetric self-renewing divisions, are at the basis of the ability of tumour SCs to grow
indefinitely and to expand geometrically in culture.
6.2 Mechanisms That Regulate SC Self-renewal
6.2.1 p53 Regulates SC Divisions
One of the key tasks of the current research is to identify critical processes that are altered in CSCs and
account for the acquired properties that could be used as targets for specific anticancer therapies against
CSCs, that may escape conventional anticancer therapies.
In recent years it has become more and more clear that p53 is involved in the regulation of SC
self-renewal, and this has been shown in neural stem cells (Armesilla-Diaz et al., 2009; Meletis et al.,
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2006; Nagao et al., 2008)and in hematopoietic SCs (Herrera-Merchan et al., 2010; Zhao et al., 2010).
Interestingly, the loss of p53 has been shown to induce the upregulation of CD44 and consequently the
expansion of tumour initiating cells in luminal breast epithelial cells (Godar et al., 2008). Finally, p53
has been reported to impose an asymmetric cell fate in MEFs and in a mammary epithelial cell line
(Rambhatla et al., 2001).
To understand the role of p53 in regulating mammary SC self-renewal, we took advantage of a knockout
mouse model where the endogenous alleles for p53 have been deleted. The pre-malignant mammary
tissue was collected from these mice and the mammary epithelial cells were purified and cultured as
mammospheres for in vitro and in vivo analyses. Indeed, p53 KO mammospheres showed increased self-
renewing potential and lifespan of SCs compared to control mammospheres (Fig 6.14), and prevalence
of symmetric SC divisions (74.9% of symmetric divisions and 14.4% of asymmetric divisions, n=190)
visualised both via time-lapse imaging (Fig. 6.15) and Numb distribution of dividing cells (Numb was
weakly cytoplasmic and uniform around the cortex in 74.4% of the p53 KO PKHhigh cells, with only 9.3%
of cells showing a membrane crescent on the membrane, n=43) (Fig. 6.16).
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Figure 6.14: Growth curve of control or p53 KO mammospheres.
Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right panel) Numbers
were obtained from serial replating of WT (black lines) and p53 KO (blue lines) mammospheres. Regres-
sion analysis of the data set was performed to obtain trend lines (light lines) that best approximate the
curves. The growth rates (GR) and the coefficients of determination (R2) for each trend line are reported
inside the graph.
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Figure 6.15: Time-lapse imaging of a forming p53 KO mammosphere.
Time-lapse microscopy images of the cell divisions during p53 KO mammosphere formation. PKHhigh cells
were purified from p53 KO mammospheres and visualised by time-lapse imaging as described. Elapsed
time after seeding is shown at each division event. Pie charts show the frequencies of different types of
divisions. Scale bars are reported.
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Figure 6.16: Numb localisation in p53 KO dividing SCs.
Confocal analysis of the distribution of Numb on the cell membrane of dividing SCs from WT or p53 KO
samples. DIC, Numb and DAPI staining and merged channels (Merge) of a representative cell are shown.
Relative frequencies of asymmetric and symmetric divisions are shown in the pie charts. Ambiguous:
Numb distribution not consistent among different confocal sections. Scale bar as reported.
These data suggest that like tumour SCs, p53 KO mammary SCs are near immortal and can be unlim-
itedly propagated, their growth curve showing similar growth rates to the ones that we had observed in
tumour mammospheres (Fig. 6.13). Furthermore, they undergo increased numbers of self-renewing divi-
sions, mainly of symmetric type, during mammosphere expansion, suggesting that p53 regulates polarity
of SC division in mammary SCs.
To investigate whether the increased self-renewal potential of p53 KO SCs is due to other secondary
genetic abnormalities that might accumulate in the absence of p53, we silenced its expression in WT
cells by infecting them with a lentiviral vector expressing a short hairpin RNA against p53 (pSICO-
p53sh). Indeed, the downregulation of p53 levels induced the expansion of the mammosphere culture, and
increased self-renewing potential in the interfered SCs (Fig. 6.17).
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Figure 6.17: RNAi silencing of p53 in WT SCs.
WT mammospheres were infected with lentiviral vectors expressing short hairpin RNAs directed against
p53 (pSico-p53sh), or with the control empty-vector (pSICO), and cultured in non-adherent conditions
for 6 days. 5,000 cells from secondary mammospheres were re-plated in quadruplicate in a serial replating
experiment (left graph; mean ± SD), and analysed by Western Blotting for the expression of p53 (right
panel). Western blots were normalised against the levels of vinculin expression.
This confirmed that the increase in self-renewal of p53 KO SCs is the direct consequence of the loss
of p53.
In vivo analysis of the behaviour of SCs in the absence of p53 confirmed that their increased self-
renewal and their ability to divide symmetrically results in the expansion of the SC pool in vitro. Indeed,
limiting dilution transplantation of cell suspensions deriving from the dissociation of WT and p53 KO
mammospheres revealed that, as for tumour mammospheres, the number of SCs in p53 KO mammospheres
was approximately three-fold higher (1:118 cells; 0.85%) than in control mammospheres (Table 6.4). The
average size of p53 KO mammospheres was ~600 cells (595±17; n=12), thus predicting a frequency of ~5
SCs per mammosphere, as that of tumour mammospheres.
Cell Injection
Table 6.4: Limiting dilution transplantation of cells from WT or p53 KO mammospheres.
Cell suspensions from WT or p53 KO secondary mammospheres were inoculated in recipient mice in
limiting dilution conditions (from 10,000 to 1 cell). Results show positive outgrowths as normal mammary
epithelium that arose 8-10 weeks after injection. SC frequencies (Estimates and upper/lower limits) were
calculated by limiting dilution analysis, as described in Material and Methods. Fitting to single hit model
is indicated by p-values > 0,05 (Fit). The significance of the difference in SC frequencies is indicated by
p-values < 0,05 (Difference).
Altogether, these data demonstrate that p53 regulates self-renewal of mammary SCs and that loss of
p53 favours the continuous expansion of mammary SCs through subsequent rounds of symmetric divisions.
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6.2.2 Impaired Function of p53 in CSCs
To determine whether p53 is responsible for the behaviour of CSCs in our tumour model, we evaluated
the mutational status of p53 in 10 samples of MMTV-ErbB2 derived tumours by exon sequencing and
could not find any mutation. Nevertheless, the analysis of the p53-mediated response to DNA damage
(induced by treatment with UV or Adriamycin) revealed that, compared to WT mammospheres, tumour
mammospheres show a lesser extent of p53 activation in response to stress. The levels of p53 were low or
undetectable in untreated WT or ErbB2 cells, and accumulated between 4 and 8 hours after treatment,
when its phosphorylation was also evident. The extent of adriamycin- or UV-induced p53 stabilisation
and phosphorylation was, however, significantly reduced in the tumour samples compared to controls (Fig.
6.18).
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Figure 6.18: p53-mediated response to DNA damage in WT and tumour mammospheres.
Cells from primary mammospheres were treated with adriamycin (2 μg/ml) or UV rays (50 J/m2) 2 days
after re-plating and collected at the indicated time points. Levels of p53 and extent of p53 serine-18 phos-
phorylation were analysed by Western Blot using specific antibodies (p53 and phS18p53 respectively).
Values below the blots refer to the densitometric analysis of the anti-p53 and anti-phS18p53 signals nor-
malised against the corresponding anti-vinculin values and expressed (at each time-point) as tumour/WT
ratio.
This observation is consistent with published data that show that p53 can be attenuated in tumours
due to the deregulation of other genes that control its activation (Miller et al., 2005).
To verify that indeed p53 is responsible for the increased self-renewing abilities of CSCs, we increased
the levels of p53 expression in tumour mammosphere by infecting them with a lentiviral vector for the
over-expression of p53 (pWPI-p53) or with an empty vector (pWPI). Analysis of the growth curve revealed
that indeed the overexpression of p53 had a moderate, yet significant, effect in decreasing the replicative
potential of CSCs (Fig. 6.19).
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Figure 6.19: p53 overexpression in tumour mammospheres.
Serial re-plating of tumour mammospheres after p53 over-expression. The graph shows the serial replating
of mammospheres infected with pWPI (red line) or pWPI-p53 (black line). Individual panels on the right
show immuno-fluorescence analysis of p53 levels in mammospheres infected with pWPI or pWPI-p53;
nuclei are counterstained with DAPI. Significance of differences between pWPI and pWPI-p53 infected
cells at passage 7 was assessed using the T-test. Scale bars as reported.
The partial effect of p53 restoration on the growth curve of tumour mammospheres may be due to
presence in these cells of other mechanisms that actively inhibit its function. It has been shown, in fact,
that the expression of ErbB2 in mammary epithelial cells induces a the downregulation of p53 by acting
on the localisation of MDM2, a ubiquitine E3-ligase that targets p53 for degradation(Zheng et al., 2004).
To circumvent this, we decided to increase the levels of p53 in tumour mammospheres by inhibiting
the activity of MDM2 with Nutlin-3, a small molecule that binds to MDM2 and impairs its function in
degrading p53(Vassilev et al., 2004). To this end, we collected, disaggregated and replated tumour and WT
primary mammospheres to form secondary mammospheres in the presence of increasing concentrations of
Nutlin-3. Indeed, we could observe by Western Blot that upon treatment with Nutlin-3 the levels of p53
in secondary mammospheres were increased in WT and tumour samples, with slightly higher levels and
a more evident dose-dependent response in the tumour mammospheres (Fig. 6.20)
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Figure 6.20: WB analysis of p53 expression following Nutlin-3 treatment.
Western Blot analysis of p53 expression in WT or tumour secondary mammospheres after treatment with
Nutlin3. Values above the blots were obtained by densitometric analysis of the anti-p53 signal normalised
against the corresponding anti-vinculin values and expressed as arbitrary units relative to the signal (=1)
of WT untreated samples.
To study the effect of Nutlin-3 on WT and tumour SCs self-renewal we measured the number of SCs
in WT and tumour mammospheres at each passage after treatment. Interestingly, while Nutlin-3 had
no effect on the number of secondary WT mammospheres, and only marginally decreased the number
of ErbB2-tumour mammospheres, disaggregation and replating of secondary mammospheres generated
tertiary mammospheres with decreasing efficiency in tumour samples (up to ~7 and ~14-folds with the
maximal drug doses of 5 and 10 μM, respectively), but still did not affect the growth WT mammospheres.
Notably, the absolute numbers of tertiary tumour mammospheres were comparable, at the highest con-
centrations of Nutlin3 (2.5, 5, and 10 μM), to those of untreated WT tertiary mammospheres(Fig. 6.21).
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Figure 6.21: Serial replating of WT and tumour mammospheres after Nutlin-3 treatment.
Cumulative Sphere Number (± SD, three independent experiments). Growth curves were obtained by
serial re-plating of WT and tumour (ErbB2) mammospheres treated with increasing concentrations of
Nutlin3 (as indicated) or DMSO (control).
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Together, these results demonstrate that Nutlin-3 induces p53 stabilisation in both WT and tumour
mammospheres, but that it reduces the frequency of self-renewing divisions only in the latter. This is
consistent with the observation that p53 directs asymmetric divisions in mammary SCs, and suggests
that Nutlin-3 reduces the frequency of self-renewing divisions selectively in tumour SCs by switching their
mode of division from symmetric to asymmetric. To provide a direct demonstration of this, we performed
time-lapse imaging of tumour PKHhighcells in the presence of Nutlin-3. Results show that the majority
of CSCs, after treatment with Nutlin-3, divided asymmetrically (75.9%, n=54). Of the remaining cells,
18.5% divided symmetrically, a proportion that is comparable to that observed in WT samples (Fig. 6.22).
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Figure 6.22: Time-Lapse analysis of Nutlin-3 treated CSCs.
Time-lapse microscopy images of the first divisions of a tumour PKHhigh cell treated with 2.5 μM Nutlin-
3. Elapsed time (from seeding) is reported inside each panel. Relative frequencies of asymmetric and
symmetric divisions are shown in the pie charts. Ambiguous: divisions that could not be interpreted as
symmetric or asymmetric. Scale bars as reported.
To exclude that Nutlin-3 acts through a p53-independent mechanism, we treated p53 KO SCs and
evaluated the effect of the treatment on their growth curve. Indeed we confirmed that Nutlin-3 had no
off-target effect as we could not appreciate any effect on the sphere-forming efficiency of p3 KO SCs (Fig.
6.23).
Figure 6.23: Effect of Nutlin-3 on p53 KO mammospheres.
Cumulative Sphere Number (± SD, three independent experiments) obtained by serial re-plating of p53
KO mammospheres treated with increasing concentrations of Nutlin3 (as indicated) or DMSO (control).
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To evaluate the biological significance of the effect of Nutlin-3 treatment on tumour SCs, we analysed
their ability to form tumours in vivo after transplantation. Secondary tumour mammospheres treated
with DMSO (control) or 2.5 μM and 10 μM Nutlin-3 were injected into recipient mice. Strikingly, after
8 weeks, CSCs that had been subjected to the treatment had formed tumours with a reduced volume
of about eight-fold compared to the untreated tumour mammospheres (Fig.6.24); however, histological
analysis of tumour sections revealed no difference in their proliferation (by Ki67 staining) or in the tissue
histology (Fig. 6.25).
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Figure 6.24: Injection of DMSO and Nutlin-3 treated mammospheres into recipient mice.
Primary tumour mammospheres were disaggregated and plated in the presence of Nutlin-3 at the indicated
concentrations. After 48 hours, the forming mammospheres were analysed for the re-expression of p53 by
WB (right panel) and injected (10,000 live cells) into the mammary glands of syngeneic mice (8 injections
per each concentration). After 2 months, the mice were sacrificed and inspected for tumour growth. All
injections gave rise to tumours. The graph (left panel) shows the measurements of tumour volumes (mean
± SD).
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Figure 6.25: Analysis of histology and proliferation in tumours deriving from the injection of
Nutlin-3 treated mammospheres.
Representative images of haematoxylin-eosin and anti- Ki67 stained sections from paraffin-embedded
tumours that arose from the injection of control or Nutlin-3-treated tumour mammospheres. Percentage
(± SD) of Ki67 positive cells is reported inside each panel (a minimum of 1,000 cells counted). Scale bars
as reported.
We then investigated the effect of Nutlin-3 on spontaneous tumours in vivo. Two month-old MMTV-
ErbB2 mice were treated with DMSO or Nutlin-3 for two weeks (one i.p. injection every two days). At
the end of the treatment, a fraction of the animals was sacrificed to evaluate the effect of the treatment
on CSCs. To this end, tumour tissues were collected, cells were purified as described and injected in
limiting dilution into recipient mice. The remaining animals were kept under observation for further two
months to evaluate the tumour growth in vivo. Indeed, treatment with Nutlin-3 resulted in the formation
of tumours with reduced volumes compared to control-treated mice (Fig. 6.26).
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Figure 6.26: Effect of Nutlin-3 treatment on spontaneous ErbB2-driven mammary tumours.
Two-month old WT or ErbB2 transgenic mice were treated i.p. with DMSO or 20 mg/kg or Nutlin-3
every 2 days for 2 weeks. Four mice per treatment group were sacrificed two months later for inspection of
tumour growth. Tumour volume (mean (± SD) for inguinal (left) and thoracic (right) mammary tumours
is shown in the graphs. All tested mice developed tumours. Measurement of the volume of thoracic
and inguinal mammary tumours showed a ~3 and ~4 fold decrease respectively in Nutlin-treated animals
compared to controls. P-values as indicated.
As assessed by limiting dilution transplantation of the tissues collected after the 2-week treatment,
Nutlin-3 reduced the content in CSCs in spontaneous tumours (Table 6.5).
Cell Injection
Table 6.5: Limiting dilution transplantation of Nutlin-3 treated mammary tumours.
Primary mammary cells from control or Nutlin-3-treated mice were injected into the cleared fat pads
(WT samples) or the mammary gland (tumour samples; ErbB2) of syngeneic mice (number of injected
cells as indicated). Results are shown as number of outgrowths or tumours per number of injections. SC
frequencies (estimates and upper - lower limits) were calculated by limiting dilution analysis, as described
in Material and Methods. Fitting to single hit model is indicated by p- values>0.05 (Fit). Differences
in SC frequencies are calculated for each sample against the DMSO-treated samples. Their significance
is indicated by p-values <0.05 (Difference). As expected, SCs frequency in the DMSO-treated ErbB2-
tumours was 9-10 fold higher than in the WT mammary gland. Nutlin3 treatment, however, markedly
reduced the frequency of SCs in the ErbB2-tumours, to an extent that was comparable to that of the WT
tissue.
Interestingly, analysis of tumour sections from DMSO and Nutlin-3 treated MMTV-ErbB2 mice re-
vealed no difference in the frequency of proliferating or apoptotic cells in the Nutlin-3 treated tumours
compared to controls, suggesting that the effect of Nutlin-3 on spontaneous tumours is solely due to the
effect that the restoration of the levels of p53 has on CSC division (Fig. 6.27).
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Figure 6.27: Effect of Nutlin-3 treatment on proliferation and apoptosis in tumour tissues.
Two-month old WT or ErbB2 transgenic mice were treated i.p. with DMSO or 20 mg/kg of Nutlin3
every 2 days for 2 weeks. Three mice per treatment group were sacrificed immediately after the treatment
to evaluate apoptosis (by anti-activated caspase3 staining) and proliferation (by anti-Ki67 staining) on
paraffin embedded mammary tissue sections. Percentage (± SD) of positive cells is reported inside the
panels (at least 1,000 cells counted). Scale bars as reported.
Together, these data demonstrate that two weeks of Nutlin-3 treatment reduced the frequency of CSCs
and delayed tumour growth, in the absence, however, of significant anti-proliferative effects on cancer cells.
These observations suggest that the increased self-renewal of tumour SCs contributes to tumour growth in
vivo, and that Nutlin-3 is able to reduce tumour development by inhibiting symmetric divisions in CSCs.
6.2.3 Myc is the Effector of p53 in Regulating Stem Cell Division
The role of p53 in regulating SC self-renewal has been described in several systems and we have provided
further data that confirm this function also in mammary epithelial cells. Nevertheless, p53 is involved in
a plethora of pathways involving responses to stress (DNA damage or oncogene activation). Therefore,
the role of p53 in the regulation of SC divisions requires further analyses to understand the mechanisms
with which this function is carried out.
It has been shown that Myc regulates self-renewal in different systems: in Drosophila the cell fate
determinant Brat, that is asymmetrically segregated in neuroblast division, downregulates Myc thereby
inhibiting self-renewal (Betschinger et al., 2006). In human neural stem or progenitor cells, Myc has been
shown to act through Miz-1 in regulating self-renewal (Kerosuo et al., 2008) and to cooperate with the
p53-p19 pathway (Nagao et al., 2008) and with Pten (Zheng et al., 2008) in controlling self-renewal and
differentiation in these cells.
Furthermore, there are several evidences showing that Myc is transcriptionally repressed by p53 in an
in vitro system (Ragimov et al., 1993)and in human and mouse cell lines (Ho et al., 2005). More recently, a
putative mechanism for this regulation has been described, involving the expression of the miR-145 micro
RNA (miRNAs) (Sachdeva et al., 2009), that is able to posttranscriptionally regulate Myc expression.
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These observations led us to hypothesise that Myc could act downstream to p53 as a general regulator of
self-renewing signals also in our models. To test this hypothesis we evaluated the expression of Myc in p53
KO mammospheres and MMTV-ErbB2 derived tumour mammospheres. To this end we cultured p53 KO
and tumour cells and collected secondary mammospheres for protein or total mRNA extraction. Because
with our antibody endogenous levels of Myc were undetectable in WT samples, we immunoprecipitated
the protein and evaluated its expression by WB. Analysis of Myc at the protein level revealed a marked
upregulation in p53 KO and tumour mammospheres compared to the WT control (Fig. 6.28). This data
was confirmed by the analysis of Myc mRNA expression by qPCR (Fig. 6.29).
WT WTTum Tump53KO p53KO
Total IPαc-Myc
c-Myc
Vinculin
Figure 6.28: Immuno Precipitation analysis of Myc expression in p53 KO and tumour mam-
mospheres.
Cell lysates from 4 million WT, p53 KO or tumour cells were incubated with a mouse monoclonal anti-
Myc antibody and protein A beads. Immunoprecipitated material was loaded onto a SDS-PAGE gel and
blotted onto a nitrocellulose membrane. Loading control was performed by visualising vinculin expression
in total lysate controls.
0
1
2
3
4
WT MMTV-ErbB2 p53 KO
p<0.002
p<0.03
c -
M y
c
( R
e l
a t
i v
e  
A m
o u
n t
)
Figure 6.29: Myc expression in WT, p53 KO and tumour mammospheres.
Myc expression in WT, p53 KO and tumour mammospheres was evaluated by Q-PCR analysis of Myc
mRNA in secondary mammospheres (means ± SD of three biological replicates). Values are expressed as
arbitrary units relative to WT samples (assigned equal to 1). Myc expression was normalised against the
rRNA 18S subunit. Significance of differences between indicated samples was assessed using the T-test.
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Analysis of Myc expression in p53 KO and tumour mammospheres revealed increased expression levels
compared to WT controls, suggesting a role for Myc in the regulation of self-renewal in p53 KO and tumour
SCs, as we had hypothesised. To confirm this idea, we used two different approaches to decrease the levels
of Myc expression in p53 KO and tumour mammospheres. First, we tried silencing Myc expression in
p53 KO and tumour mammospheres by infecting the cells with a lentiviral vector for specific Myc RNA
interference (pLKO-c-Myc-shRNA) or a control vector (pLKO). However, probably due to the fact that
Myc is essential for cell survival (Davis et al., 1993), the silencing resulted in the arrest in cell growth and
infected cells could not be passaged further (Fig 6.30).
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Figure 6.30: Myc RNAi in p53 KO mammospheres.
Representative images of tertiary p53 KO mammospheres infected with an empty vector (pLKO) or a
vector carrying short hairpin RNA against Myc (pLKO-c-Myc-shRNA). Interference of Myc in secondary
mammospheres resulted in cell growth arrest and prevented the formation of tertiary mammospheres.
Scale bars as represented.
As an alternative approach, we expressed in p53 KO mammospheres a mutant form of Myc (Omomyc),
that acts as a dominant negative protein that is able to bind and sequester the endogenous Myc, thus
preventing its activity as transcription factor(Soucek et al., 1998). Once again, the inhibition of Myc
function with the Omomyc mutant turned out to be incompatible with cell growth and we could not
observe the formation of mammospheres (Fig. 6.31).
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Figure 6.31: Omomyc expression in p53 KO mammospheres.
Representative images of tertiary p53 KO mammospheres infected with an empty vector (Ctrl) or a vector
carrying the dominant negative Myc (Omomyc). Expression of Omomyc in secondary mammospheres
resulted in cell growth arrest and prevented the formation of tertiary mammospheres. Scale bars as
represented.
In light of these observations, we decided to adopt an indirect approach to verify that Myc is responsible
for the increased self-renewing properties of CSCs and that it acts in the same pathway as p53. We have
shown that p53 imposes an asymmetric mode of division onto SCs and that if absent or impaired, SCs
divide symmetrically thus expanding in number. Interestingly, we have noted that in those systems where
SCs divide prevalently symmetrically, Myc is expressed at higher levels. Taken together, these observations
lead to the postulation of a model where the absence of p53 results in symmetric SC division through
the (direct) regulation of Myc expression. Given that the restoration of the levels of p53 expression in
tumours leads to a switch in the SC mode of division from symmetric to asymmetric, we expect that this
effect is carried out through downregulation of Myc. To uncouple the p53 and Myc pathways, we enforced
the expression of Myc in tumour mammospheres by infecting them with a lentiviral construct carrying
the sequence for human Myc fused with a modified estrogen receptor (MycER), conditionally tunable by
treatment with 4-HydroxiTamoxifen (4-OHT) (Littlewood et al., 1995). In this scenario, and according
to our model, modulation of p53 expression would not have any effect on an exogenously regulated Myc.
We then restored the levels of p53 in MycER-expressing tumour mammospheres by treating them with
Nutlin-3 as previously described. If, as hypothesised, Myc is negatively regulated by p53 to control self-
renewing divisions in SCs, the restoration of p53 levels in tumour mammospheres that would determine
a switch in self-renewing divisions from a symmetric to an asymmetric mode, would not have any effect
in the context of exogenously expressed MycER (see schematic representation in Figg. 7.3, 7.4 and 7.5 of
the Discussion section).
Indeed, expression of MycER in Nutlin-treated tumour mammospheres rendered the treatment inef-
fective, and disaggregation and replating of treated secondary mammospheres resulted in the formation of
tertiary spheres with a high frequency as compared to control tumour cells treated with Nutlin-3. Thus,
in the context of enforced expression of Myc, the restoration of p53 levels in tumour mammospheres is
not sufficient to decrease CSCs self-renewing properties, suggesting that indeed Myc acts downstream to
p53 in this pathway (Fig. 6.32).
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Figure 6.32: Serial replating of control or MycER-expressing tumour mammospheres after
Nutlin-3 treatment.
Cumulative Sphere Number (± SD, one representative experiment of three independent experiments
that have given similar results). Growth curves were obtained by serial re-plating of control tumour
mammospheres (MMTV-ErbB2) or tumour mammospheres expressing MycER (MMTV-ErbB2-c-Myc)
treated with increasing concentrations of Nutlin3 (as indicated) or DMSO (control). Arrows indicate
moment of Nutlin-3 treatment.
6.3 Enforced Expression of Myc in Mammary Stem Cells
We have shown that CSCs mainly divide symmetrically, and that this is due to an impaired function of
p53, as demonstrated by the fact that restoration of its levels in CSCs induces a switch in the mode of
SC division from symmetric to asymmetric. Furthermore we have shown that the absence of p53 results
in an upregulation of Myc, a known regulator of self-renewal in several systems. We show evidences that
Myc acts downstream to p53 in this pathway and in particular, that it is negatively regulated by p53,
as the restoration of p53 levels in CSCs that exogenously expressed a MycER protein did not result in a
switch in the mode of SC division from symmetric to asymmetric.
We wondered whether Myc alone could be responsible for an increase in the self-renewing abilities of
SCs or if in our tumour and p53 KO systems it cooperates with other factors to achieve this effect. To
address this point we expressed Myc in WT SCs to verify how its upregulation would modulate their
self-renewing properties.
6.3.1 High Levels of Myc Expression Induce a p53-Dependent Checkpoint
To express Myc in WT SCs, we infected primary WT mammospheres with a lentiviral vector expressing
MycER, sorted infected cells by GFP reporter gene expression, and cultured the cells as mammospheres
in the presence of 500 nM 4-OHT. As already described, at each passage we plated 5,000 control or
MycER-infected cells in 24-well low adhesion plates, monitored the formation of mammospheres and
measured their growth curve. Interestingly, the induction of MycER prevented the formation of secondary
mammospheres; the few cells surviving the treatment could not be passaged further (Fig. 6.33).
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Figure 6.33: Behaviour of mock and MycER infected cells after 4-OHT treatment.
Upper panel: Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right
panel) Numbers were obtained from serial replating of WT mock-infected (black lines, WT pWPI) and
MycER-infected (red lines, WT MycER) mammospheres after 4-OHT treatment. Regression analysis of
the data set was performed to obtain trend lines (light lines) that best approximate the curves. The
growth rates (GR) and the coefficients of determination (R2) for each trend line are reported inside the
graph.
Table: average mammosphere size between the different passages. We have demonstrated that mammo-
sphere size remains constant at every passage (Cicalese et al., 2009). Mock-infected and Tamoxifen-treated
mammospheres were composed of approximately 300 cells, as previously reported (Section 6.1). MycER-
expressing cells did not form mammospheres upon 4-OHT treatment.
Lower panel: representative images of mock-infected secondary mammospheres or MycER-infected cells
after 6 days of exposure to 4-OHT. Scale bars as represented.
To exclude any off-target for the treatment with 4-OHT, we cultured mock-infected cells in the absence
or in the presence of 500 nM 4-OHT. We could not notice any significant alteration of the growth curve
or the mammosphere size of the treated cells compared to the untreated sample (Fig. 6.34).
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Figure 6.34: Effect of Tamoxifen treatment on mock-infected cells.
Upper panel: Semi-logarithmic plotting of Cumulative Sphere Numbers (left panel) were obtained from
serial replating of WT mock-infected mammospheres in the absence (black lines, WT pWPI-4-OHT) and
in the presence (red lines, WT pWPI+4OHT) of 500 nM 4OHT. Regression analysis of the data set was
performed to obtain trend lines (light lines) that best approximate the curves. The growth rates (GR) and
the coefficients of determination (R2) for each trend line are reported inside the graph. Right panel: WT
mock-infected mammosphere size over passages in the absence (black line) or in the presence of 4-OHT
(red line).
Lower panel: representative images of mock-infected secondary mammospheres in the presence of the
absence of 4-OHT. Scale bars as represented.
We evaluated the expression and localisation of MycER in infected cells by immunofluorescence stain-
ing. Whereas in the mock-infected cells the endogenous Myc was undetectable, in the MycER-infected
cells, treatment with 4-OHT induced an overexpression of Myc and indeed it could be found localised at
the nuclei (Fig. 6.35).
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Figure 6.35: Myc expression and localisation in control or MycER-expressing cells.
Single-cell suspensions from secondary mammospheres were fixed with 4% paraformaldehyde, perme-
abilised with 0.1% Triton-X100 and blocked in 3% BSA in PBS. Staining was performed with a Myc-
specific antibody, followed by an anti-rabbit Cy5 antibody. Nuclei were counter-stained with DAPI. The
cells were then analysed under an AX-70 Provis (Olympus) fluorescence microscope to evaluate Myc
expression.
We reasoned that the growth arrest that we observed in response to MycER activation could be due
to an apoptotic response, and to address this we evaluated the expression of cleaved caspase-3 by Western
Blot (WB) analysis. We infected primary mammospheres with the empty vector or with MycER and
allowed for secondary mammospheres to form. We then disaggregated, sorted for GFP expression and
replated secondary mammospheres in the presence or in the absence of 4-OHT. Treatment was carried
out either once on the day of replating (+s), or every day during mammosphere formation (+d). Both in
the single-treated and the daily-treated mammospheres we observed a significant increase in the levels of
cleaved caspase-3, suggesting that these cells undergo apoptosis upon overexpression of Myc (Fig. 6.36).
- +s +d - +s +d
pWPI pWPI-c-MycER
Cleaved
Caspase-3
Vinculin
4-OHT:
Figure 6.36: WB analysis of cleaved caspase-3 expression.
Western Blot analysis of cleaved caspase-3 expression in WT mammospheres infected with control vector
(pWPI) or MycER (pWPI-MycER) and exposed to no treatment (-), single treatment on the day of
replating (+s) or daily treatment during mammosphere formation (+d). Western blots were normalised
against the levels of vinculin expression.
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To characterise the checkpoint that was triggered in response to the overexpression of MycER, the
same cells were analysed by WB for the activation of the p53 pathway and the p21 pathway, two key
regulators of oncogene-induced checkpoints (Bartkova et al., 2006). Strikingly, we could observe massive
activation of the p53, p21 and p16 proteins in 4-OHT treated cells compared to mock-infected cells (Fig.
6.37).
- +s +d - +s +d
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p16
Vinculin
4-OHT:
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Figure 6.37: WB analysis of the checkpoint activation in response to Myc overexpression.
Western Blot analysis of the expression of p53, p21 and p16 in WT mammospheres infected with control
vector (pWPI) or MycER (pWPI-MycER) and exposed to no treatment (-), single treatment on the day
of replating (+s) or daily treatment during mammosphere formation (+d). Western blots were normalised
against the levels of vinculin expression.
To confirm that indeed the checkpoint that is triggered upon Myc activation is dependent on p53, we
infected p53 KO mammospheres with the MycER construct and treated the cells with 500 nM 4-OHT.
As expected, treatment of infected p53 KO mammospheres with 4-OHT did not affect their growth,
suggesting that p53 is required for the activation of the checkpoint and the growth arrest in response to
Myc activation (Fig. 6.38).
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Figure 6.38: Growth curve of p53 KO or WT MycER-infected mammospheres upon 4-OHT
treatment.
Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right panel) Numbers
were obtained from serial replating of p53 KO (black lines, p53 MycER) and WT (red lines, WT MycER)
mammospheres upon treatment with 500 nM 4-OHT. Regression analysis of the data set was performed
to obtain trend lines (light lines) that best approximate the curves. The growth rates (GR) and the
coefficients of determination (R2) for each trend line are reported inside the graph.
These data suggest that upon Myc overexpression, mammary SCs activate a p53-dependent pro-
apoptotic checkpoint that induces growth arrest.
6.3.2 Low Levels of Myc Expression Increase SC Self-Renewal Without Inducing Trans-
formation
The activation of an apoptotic checkpoint in response to the expression of Myc in our system did not
help us in elucidating the role of this protein in the regulation of self-renewal of mammary SCs. However,
quite unexpectedly, the same MycER-infected cells showed a striking phenotype in the absence of 4-OHT
treatment. In fact, if cultured as mammospheres without being exposed to 4-OHT, these cells showed a
remarkable increase in their self-renewing potential and could be passaged indefinitely in a manner similar
to tumour or p53 KO SCs. Furthermore, the absence of 4-OHT induction resulted also in a dramatic
increase of mammosphere size compared to controls, suggesting that they possessed increased replicative
potential (Fig. 6.39).
C u
m u
l a
t i
v e
 S
p h
e r
e  
N u
m b
e r
 C
u m
u l
a t
i v
e  
C e
l l
 N
u m
b e
r
1 2 3 4 5 6 1 2 3 4
10
10
1
3
WT pWPI-4OHT
G.R.= 0.65
R = 0.94
WT MycER-4OHT
G.R.= 13.05
R = 0.99
2
2
PassagePassage
5 6
WT pWPI-4OHT
G.R.= 0.66
R = 0.93
WT MycER-4OHT
G.R.= 12.67
R = 0.99
2
2
105
103
105
10710
7
WT pWPI-4OHT WT MycER-4OHT
Sphere Size
Cell Nr
WT pWPI-4OHT
WT MycER-4OHT
384.5
3085.7
68
6.3 Enforced Expression of Myc in Mammary Stem Cells 6 RESULTS
Figure 6.39: Growth curve of control or MycER infected cells in the absence of 4-OHT
treatment.
Upper panel: Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right
panel) Numbers were obtained from serial replating of WT mock-infected (black lines, WT pWPI) and
MycER-infected (red lines, WT MycER) mammospheres. Regression analysis of the data set was per-
formed to obtain trend lines (light lines) that best approximate the curves. The growth rates (GR) and
the coefficients of determination (R2) for each trend line are reported inside the graph.
Table: average mammosphere size between the different passages. We have demonstrated that mammo-
sphere size remains constant at every passage (Cicalese et al., 2009). Mock-infected mammospheres were
composed of approximately 350 cells, as previously reported (Section 6.1). MycER-expressing mammo-
spheres showed drastic increase in size (~3,000 cells).
Lower panel: representative images of mock-infected secondary mammospheres or MycER-expressing
mammospheres after 6 days of culture. Scale bars as represented.
We reasoned that the remarkable phenotype that we observed upon infection of MycER without the
4-OHT-mediated induction, could be due to a leakage in the ER conditional system and to investigate
this issue we evaluated the expression of Myc in these cells by immunofluorescence. As hypothesised, the
levels of Myc expression in the nuclei of 4-OHT untreated cells were lower compared to the ones observed
in induced cells, but higher than the mock-infected control, where the endogenous Myc could not be
detected (Fig. 6.40).
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Figure 6.40: Immunofluorescence staining for Myc expression in control or 4-OHT treated or
untreated MycER-infected cells.
Staining of single-cell suspension from secondary WT mammospheres infected with control vector (left
panels) or MycER in the absence (middle panels) or in the presence (right panel) of 4-OHT treatment
with a Myc-specific antibody. Single-cell suspensions from secondary mammospheres were fixed with
4% paraformaldehyde, permeabilised with 0.1% Triton-X100 and blocked in 3% BSA in PBS. Staining
was performed with a Myc-specific antibody, followed by an anti-rabbit Cy5 antibody. Nuclei were
counter-stained with DAPI. The cells were then analysed under an AX-70 Provis (Olympus) fluorescence
microscope to evaluate Myc expression.
These data suggest that whereas high levels of Myc expression (such as the ones resulting from the
induction of the ER system) induce a p53-dependent pro-apoptotic checkpoint, low levels of Myc expression
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(such as the ones that result from the leakage of the ER system) are able to confer increased regenerative
potential (mammosphere size) and lifespan (extended serial replating efficiency) to mammary epithelial
SCs.
To confirm that the acquired self-renewing properties of mammary SCs in the presence of the MycER
protein at low levels were not an effect of the ER system, we expressed a constitutive form of Myc in WT
mammospheres by lentiviral infection. Unfortunately, probably due to the fact that the Myc gene was
expressed under the control of a strong promoter (CMV), the high levels of Myc expression that resulted
from the infection did not induce an increase in the self-renewing abilities of WT SCs (Fig. 6.41).
Figure 6.41: Infection of WT mammospheres with a constitutive Myc.
Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right panel) Numbers
were obtained from serial replating of mock-infected (black lines, WT pRDI) and Myc-expressing (red
lines, WT Myc) mammospheres. Regression analysis of the data set was performed to obtain trend lines
(light lines) that best approximate the curves. The growth rates (GR) and the coefficients of determination
(R2) for each trend line are reported inside the graph.
To circumvent this problem, we expressed the constitutive Myc vector in WT mammospheres at lower
levels by infecting the cells with decreasing concentrations of lentiviral supernatant, in such a way that
different integration efficiencies could be achieved. In this way, we hoped to obtain the formation of
clones that expressed sufficient amounts of the Myc protein to induce proliferation without activating a
pro-apoptotic checkpoint. We cultured the infected cells to verify the emergence of an immortal clone in
these mammosphere cultures. Indeed, at low virus titers, we could observe the emergence of immortal
clones that possessed increased self-renewing abilities (Fig. 6.42).
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Figure 6.42: Infection of WT mammospheres with a constitutive Myc at different virus titers.
Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right panel) Numbers
were obtained from serial replating of cells infected with a control vector (pRDI) or with the constitutive
Myc vector (pRDI-Myc) at different viral titers (numbers indicate the dilution factors of the viral super-
natant). One representative experiment of two that gave similar results. Regression analysis of the data
set was performed to obtain trend lines that best approximate the curves (not shown). The growth rates
(GR) and the coefficients of determination (R2) for each trend line are reported in the tables below the
curves.
The increase in the replicative potential of WT SCs expressing low levels of a constitutive Myc also
correlated with an increase in the mammosphere size and in the estimated number of SCs per sphere,
calculated as the mean of the number of sphere-forming cells per dissociated sphere at every passage (Fig.
6.43).
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Figure 6.43: Sphere dimension and estimated SC number after Myc infection at different
titers.
Mean sphere dimension and mean number of SC per sphere over passages in mammosphere cultures
from mock-infected (pRDI) or constitutive Myc-expressing mammospheres (c-Myc) infected with different
concentrations of viral supernatant. At each passage 5,000 cells were plated in 24-well low adhesion plates.
After 6 days the number of formed spheres was counted and the spheres were collected and disaggregated
to count the number of total cells. Sphere dimensions were calculated at each passage as the ratio between
the total number of cells and the number of spheres that were counted. The number of SCs per sphere was
estimated as ratio between the number of counted spheres and the number of plated spheres (equivalent
to 5,000 cells, as estimated by the calculated sphere dimension). Figures show representative images of
mammospheres that were formed after infection with the empty vector or the constitutive Myc at different
titers. Scale bars as represented (100 μm).
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To exclude that the effect of low expression of Myc on SCs was limited to the mouse system, we
cultured as mammospheres normal human mammary epithelial cells purified from reductive mammoplas-
ties, following published protocols (Dontu et al., 2003; Pece et al., 2010). We then infected the human
mammospheres with the MycER construct and could observe that, compared to the normal counterpart
that exhausted in culture after few passages, the MycER-expressing spheres had acquired an immortal
phenotype, and showed increased sizes, thus confirming that the effect of low levels of Myc is not restricted
to mouse SCs (Fig. 6.44).
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Figure 6.44: Infection of human mammospheres with MycER.
Plotting of Cumulative Cell Numbers were obtained from serial replating of human mammary epithelial
cells infected with a control vector (pWPI, black line) or with the MycER vector (MycER, red line).
Figures show representative images of human mammospheres infected with the control vector or with
MycER. Scale bars as represented.
As high levels of Myc expression resulted in the activation of a p53-mediated apoptotic checkpoint in
mammary SCs, we investigated if a similar response could be triggered by low levels of Myc . Interestingly,
the expression of Myc at low levels had no effect on the activation of p53, p21, or p16 (Fig. 6.37).
To confirm that indeed low levels of Myc expression had no effect on the function of p53, we evaluated
the extent of the p53-mediated response to stress in low Myc-expressing mammospheres. To this end,
we treated low Myc-expressing and control mammospheres with 2 μg/ml adriamycin and measured the
levels of activation of p53 by immunoblotting its phosphorilated form in Ser18. Both in control-infected
and MycER-expressing mammospheres the treatment with the the DNA-damaging agent resulted in the
stabilisation of the p53 protein and in its phosphorilation on Ser18. This showed that activation of p53
in response to stress was not impaired in the presence of low levels of Myc, thus confirming that low Myc
does not activate a p53-mediated response nor does it act on its function, supporting the idea that Myc
is regulated by p53 in controlling SC self-renewal (Fig. 6.45).
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Figure 6.45: WB analysis of p53 activation in response to stress in the context of low Myc
expression.
Western Blot analysis of the stabilisation of p53 and its phosphorilation in response to DNA-damage.
Western blots were normalised against the levels of vinculin expression. Control mammospheres (pWPI)
and low Myc-expressing mammospheres (pWPI-c-MycER) were cultured in the presence or in the absence
of adriamycin. As positive control for the activation of p53, we induced the expression of high levels of
Myc by treating MycER-infected cells with 4-OHT once (+s) or daily during mammosphere formation
(+d). Western blots were normalised against the level of vinculin expression.
In line with these observations, the expression of low levels of Myc in p53 KO mammospheres did not
have any increasing effect on their growth rate, and low Myc expression had identical effects (in terms of
replicative potential and lifespan) on WT or p53 KO mammospheres (Fig. 6.46).
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Figure 6.46: Growth curves of WT or p53 KO mammospheres expressing low levels of Myc
Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right panel) Numbers
were obtained from serial replating of WTmammospheres infected with MycER or p53 KOmammospheres
infected with a control vector (pWPI) or MycER. Regression analysis of the data set was performed
to obtain trend lines that best approximate the curves (not shown). The growth rates (GR) and the
coefficients of determination (R2) for each trend line are reported for each curve under the graphs. The
effect of low levels of Myc is similar in WT and p53 KO mammospheres and also similar to the effect of
the absence of p53 alone.
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These data altogether show that low levels of Myc expression increase the self-renewing properties of
SCs, albeit not triggering the activation of any p53-mediated response. This observation suggests that
low levels of Myc do not create a selective pressure to lose the p53-mediated checkpoint response.
We then wondered how Myc biologically influences the behaviour of mammary SCs, as we had demon-
strated that low levels of Myc expression are able to i) increase the number of SCs (evaluated as the number
of SCs per mammosphere, ii) confer extended self-renewing abilities to SCs (which results in unlimited
serial replating of the mammospheres), iii) increase the regenerative and proliferative potential of SCs
(that are able to form mammospheres with increased size). We therefore investigated whether low Myc-
expressing SCs are transformed and to answer this question we performed transplantation experiments in
which we injected cell suspensions deriving from the dissociation of low Myc-expressing mammospheres
into the cleared fat-pad of syngeneic mice. Two months after the injection, the transplanted mice were
sacrificed and the mammary gland collected for whole mount staining to evaluate the presence of positive
outgrowths. Indeed, after two months, we were able to find positive outgrowths deriving from the injection
of low Myc-expressing cells, and, interestingly, the morphology of the epithelial tree that was generated
showed no alteration, suggesting that low Myc-expressing SCs did not have a transformed phenotype (Fig.
6.47).
Figure 6.47: Whole mount staining of a positive outgrowth resulting from the injection of low
Myc expressing cells in the cleared fat-pad of recipient mice.
Carmine-stained whole mount of typical outgrowths after injection of cell suspension from low Myc-
expressing secondary mammospheres. Scale bars as indicated.
Prolonged observation of injected mice revealed no formation of palpable masses up to 7 months after
the injection (20 animals under observation), suggesting that low Myc-expressing mammospheres are
immortalised but do not show a transformed phenotype.
These data show that the biological effect of low levels of Myc on SCs is not the result of a transforming
process, as low Myc-expressing SCs behave like normal SCs if injected into recipient mice.
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6.4 The Consequence of Low Myc Expression on Mammosphere Cultures
Can Be Explained by a Dual Effect on SCs and Progenitors
We have shown that low levels of Myc result in an increase in the number of SCs, and they are able to
confer extended self-renewing properties and increased regenerative (proliferative) potential. Biologically,
this effect could be explained by two different mechanisms depending on whether Myc targets the SC
or the progenitor cell. In fact, we have shown that Myc is regulated by p53 and that in turn it has an
effect in controlling SCs self-renewal, as shown for tumour mammospheres. This results in the expansion
of the number of SCs, nevertheless, we can not rule out the possibility that the effect of low Myc on
mammosphere cultures is due to an effect on progenitor cells, where it could induce reprogramming into
cells with stem-like properties, thus increasing their number.
To address this issue we took advantage of the PKH protocol that we had set up and validated for
the isolation of SCs from the bulk of the mammospheres and that led us to the characterisation of their
self-renewing properties, and analysed the effect of low levels of Myc on separate populations of stem or
progenitor cells.
6.4.1 Low Levels of Myc Induce SC Symmetric Division
To investigate whether low levels of Myc have an effect on SC divisions, we analysed the symmetry
of SC division by isolating the PKHhighquiescent population from low Myc-expressing or mock-infected
mammospheres and visualising the first rounds of cell divisions during mammosphere formation by time-
lapse imaging. Indeed, as we had previously observed in CSCs or p53 KO SCs, the majority of low
Myc-expressing SCs divided symmetrically, giving rise to two daughter cells endowed with the same
replicative potential (Fig. 6.48).
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Figure 6.48: Time-lapse analysis of low Myc-expressing SCs.
Time-lapse microscopy images of the first divisions of mock-infected of low Myc-expressing PKHhigh cell.
Relative frequencies of asymmetric and symmetric divisions are shown in the pie charts. Ambiguous:
divisions that could not be interpreted as symmetric or asymmetric.
These data were confirmed also by staining control or low Myc-expressing SCs with an anti-Numb
antibody as previously described, to evaluate by confocal microscopy the symmetry of distribution of
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Numb on the cell membrane. Indeed, our previous observations were confirmed, as the majority of low
Myc-expressing SCs showed symmetric distribution of Numb on the cell membrane during cell division
(Fig. 6.49).
W T
 p
W P
I
W T
 M
y c
E R
Figure 6.49: Numb localisation in dividing low Myc-expressing SCs.
Confocal analysis of the distribution of Numb on the cell membrane of dividing SCs from control or low
Myc-expressing samples. Representative images of the different modes of division are shown. Relative
frequencies of asymmetric and symmetric divisions of control (pWPI) or low Myc expressing (WTMycER)
cells are shown in the pie charts. Ambiguous: Numb distribution not consistent among different confocal
sections.
These results show how low levels of Myc expression alone endow mammary SCs with increased
proliferative potential by determining a switch in the mode of SC division from an asymmetric to a
symmetric one, thus expanding the SC pool.
6.4.2 Low Levels of Myc Expression Induce Reprogramming of Progenitor Cells Into Cells
With Stem Properties
Reprogramming of adult differentiated cells into pluripotent SCs has been achieved in recent years by
expressing the embryonic-specific factors Myc, Klf, Oct4 and Sox2(Wernig et al., 2007; Takahashi and
Yamanaka, 2006; Okita et al., 2007) . In particular, Myc has been shown to enhance the efficiency of so-
matic cell reprogramming into pluripotent cells by a thousand-fold (Nakagawa et al., 2008). Furthermore,
if expressed by itself in human fibroblast, it has shown to give a strong embryonal stem-like transcription
pattern (Sridharan et al., 2009). It is therefore reasonable to hypothesise that Myc alone could be able
to reprogramme mammary progenitors into cells with tissue-specific adult SC properties. To address this
issue, we separated mammary progenitor cells from SCs by means of the PKH26 labelling system we had
previously set up. We have shown that the rapidly dividing populations of cells (identified as PKHlowand
PKHneg) do not contain cells capable to form mammospheres in vitro nor to repopulate the cleared fat-pad
of recipient mice if injected in vivo. To test the effect of low levels of Myc on progenitor cells we focused
on the PKHnegpopulation, to limit as much as possible the probability of cross-contamination between
the PKH subpopulations. PKHnegcells were infected with the MycER construct or the empty vector and
cultured in suspension. Strikingly, whereas the mock-infected progenitor cells, as expected, were not able
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to form mammospheres even at the first passage, the low Myc-expressing progenitors were able to grow
in culture and form mammospheres. These mammospheres could be propagated in vitro unlimitedly and
expanded in culture at each passage (Fig. 6.50).
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Figure 6.50: Growth curves of progenitor cells expressing low levels of Myc.
Upper panel: Semi-logarithmic plotting of Cumulative Sphere (left panel) and Cumulative Cell (right
panel) Numbers were obtained from serial replating of mock-infected (black lines, PKHnegpWPI) and
MycER-infected (red lines, PKHneg MycER) progenitor cells. Regression analysis of the data set was
performed to obtain trend lines (light lines) that best approximate the curves. The growth rates (GR)
and the coefficients of determination (R2) for each trend line are reported inside the graph.
Tables: average mammosphere size during passages. We have demonstrated that mammosphere size
remains constant at every passage (Cicalese et al., 2009). Mock-infected PKHneg cells did not form mam-
mospheres, but only small aggregates that could not be passaged further.MycER-expressing PKHnegcells
were able to form mammospheres. Average number of SCs per sphere is also reported. The number of
SCs per sphere was estimated as ratio between the number of counted spheres and the number of plated
spheres (equivalent to 5,000 cells, as estimated by the calculated sphere dimension).
Lower panel: representative images of mock-infected of low Myc-expressing primary and secondary mam-
mospheres after infection. Scale bars as represented.
Again, to confirm that the phenotype was not due to the ER system, we infected progenitor cells with
a constitutive Myc construct at low titers, and indeed we obtained similar results (Fig. 6.51).
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Figure 6.51: Infection of progenitor cells with constitutive Myc at low titers.
Representative images of PKHnegprogenitor cells 6 days after infection with a control vector (pRDI) or a
constitutive Myc (pRDI-Myc) at low titers. Scale bars as represented.
Adult SCs are defined by their ability to self-renew and to differentiate into all the cell types of the
tissue of origin. We have demonstrated by in vitro culture assay that upon expression of Myc at low
levels, mammary progenitor cells acquire self-renewing properties and can form mammospheres that can
be serially passaged. To investigate whether these cells were able to differentiate into different cell types
in the mammary gland, we transplanted these cells into the cleared fat-pad of recipient mice. After
two months the mice were sacrificed and their inguinal mammary glands were collected for whole mount
staining to evaluate the presence of positive outgrowths. Strikingly, we could observe, although with low
frequencies, positive outgrowths resulting from the injection of low Myc-expressing cells. The epithelial
tree that was formed showed no macroscopical differences compared to the epithelial tree that is formed
upon transplantation of WT SCs (Fig. 6.52).
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Figure 6.52: Whole mount staining of a positive outgrowth resulting from the injection of low
Myc expressing progenitor cells in the cleared fat-pad of recipient mice.
Carmine-stained whole mount of typical outgrowths after injection of cell suspension from low Myc-
expressing secondary mammospheres. Scale bars as indicated.
These data demonstrate that low levels of Myc expression are able to induce reprogramming of pro-
genitor cells into cells with stem properties, although with low frequencies.
6.4.3 Low Myc-Induced Reprogramming is Associated With Genomic Instability
We have shown that high levels of Myc expression are associated with a p53-dependent apoptotic response,
resulting in the rapid exhaustion of the mammosphere culture. Low levels of Myc expression do not trigger
a p53-dependent response, however, we checked for the presence of genomic instability in these cells. To
this end, we cultured for 9 passages low Myc-expressing mammospheres at which point the mammospheres
were collected, disaggregated, and the cell suspension was serially diluted to obtain single SC clones that
were plated in 48-well plates. These clones were expanded for further 3-6 weeks, and then genomic
DNA was prepared. Comparative genomic hybridisation assays on chromosomes 10, 11, 12, 13 and part
of chromosomes 9 and 14 (covering about a quarter of the mouse genome) were then performed using
as control non-infected mammospheres at passage 5. Five clones of reprogrammed SCs were analysed
and all five showed genomic aberrations. Interestingly, all aberrations were localised on known fragile
sites. In particular, one clone presented the deletion of about 100 Kbp localised within the retinoic acid
receptor-related orphan receptor A (Rora) on chromosome 9 (Fig. 6.53).
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Figure 6.53: Comparative genomic hybridisation chromosome 9.
Comparative genomic hybridisation analysis of five MycER-reprogrammed stem cell clones. Clones 3a,
3b and 3c are considered to be subclones of the same original clone. Selected regions of chromosome 9
are indicated. The results are expressed as log2 ratios of the intensity signals of the stem cell clone DNA
to the control DNA. Each black bar represents the average of 10 probes with 1,388 bp median spacing.
The red lines represent the statistical average and show discontinuities, when a series of averaged probe
data deviates in a statistically significant manner from its neighbours. Transcripts are indicated by blue
lines and the names of select genes are indicated.
The Rora gene, in humans, maps to the common fragile site FRA15A (Bignell et al., 2010; Zhu
et al., 2006). The second clone had a deletion of about 250 Kbp on chromosome 13 spanning within the
phospohodiesterase 4D (Pde4D) gene (Fig.6.54).
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Figure 6.54: Comparative genomic hybridisation chromosome 13.
Comparative genomic hybridisation analysis of five MycER-reprogrammed stem cell clones. Clones 3a,
3b and 3c are considered to be subclones of the same original clone. Selected regions of chromosome 13
are indicated. The results are expressed as log2 ratios of the intensity signals of the stem cell clone DNA
to the control DNA. Each black bar represents the average of 10 probes with 1,388 bp median spacing.
The red lines represent the statistical average and show discontinuities, when a series of averaged probe
data deviates in a statistically significant manner from its neighbours. Transcripts are indicated by blue
lines and the names of select genes are indicated.
Again, the human homologue of Pde4D is situated within the common fragile site FRA5H (Zhu et al.,
2006).
Interestingly, the remaining three clones had identical chromosomal rearrangements suggesting that
they had originated from an identical clone prior to the serial dilution analysis. This rearrangement
targeted telomeric regions of chromosomes 9 and 10 (Fig.6.55) and the breakpoints were within the high
mobility group AT-hook2 (Hmga2) genes and the ubiquitin specific peptidase 4 (Usp4) gene respectively.
These sites are often rearranged in human cancers (Gray et al., 1995; Cleynen and Van de Ven, 2008).
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Figure 6.55: Comparative genomic hybridisation chromosomes 9 and 10.
Comparative genomic hybridisation analysis of five MycER-reprogrammed stem cell clones. Clones 3a,
3b and 3c are considered to be subclones of the same original clone. Selected regions of chromosomes
9 and 10 are indicated. The results are expressed as log2 ratios of the intensity signals of the stem cell
clone DNA to the control DNA. Each black bar represents the average of 10 probes with 1,388 bp median
spacing. The red lines represent the statistical average and show discontinuities, when a series of averaged
probe data deviates in a statistically significant manner from its neighbours. Transcripts are indicated by
blue lines and the names of select genes are indicated.
Altogether these data show that the expression of low levels of Myc in mammary epithelial cells, that
is associated with reprogramming of progenitor cells into cells with adult SC properties, induces genomic
instability and results in chromosomal aberrations that are localised in common fragile sites. Strikingly, no
further rearrangements were accumulated during the single clone expansion, suggesting that the genomic
instability in mammary SCs had been a transient event, possibly associated with the reprogramming itself.
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7.1 Self-Renewing Divisions in Mammary SCs
Stem cells are defined by their ability to self-renew and to differentiate into all the cell types that compose
their tissue of origin. With these two fundamental abilities, SCs ensure the constant maintenance of
homoeostasis in the hierarchically organised tissue, and, if needed, they can undergo several rounds of
cell division without being lost. The failure of the mechanisms that regulate these processes inevitably
results in an aberrant development of the tissue, and contributes to the formation of cancer. Interestingly,
tumours are complex and heterogeneous tissues composed of a mass of diverse cell subtypes, sustained by
a limited number of cells that for this reason are called CSCs. CSCs have been identified in several solid
tumours as well as in haematopoietic diseases, yet their understanding is still very preliminar. Several
important and unsolved questions are being addressed by numerous research groups, as, for example,
what could be the origin of these cells and which are the mechanisms that are altered and render them
transformed. Because of the properties that CSCs share with normal SCs, it is reasonable to hypothesise
that they are generated following the loss of regulating mechanisms in normal SCs. After the identification
and isolation of SCs in the haematopoietic system, which served as a paradigm for subsequent studies,
cells endowed with the ability to sustain the balanced turnover of a tissue have been identified in several
systems, including the mammary gland (Stingl et al., 2006; Shackleton et al., 2006). We took advantage
of this system to investigate what are the alterations that characterise CSCs and that render them able
to grow, insensitive to the regulatory mechanisms that normally control tissue homoeostasis.
7.1.1 Extended Replicative Potential and Increased Frequency of Symmetric Divisions in
CSCs
Based on published protocols for the purification and culture of mammary SCs, we were able to set up
a culturing system for the propagation of mouse mammary SCs, from both normal and tumour samples.
In these cultures, the content in SCs was evaluated with assays in vitro (i.e. the ability of SCs to form
mammospheres that could be propagated in culture and complex threedimentional structures in semisolid
matrix) and in vivo (the ability to repopulate the cleared fat-pad of a mouse forming normal tissues or
tumours with the same complexity of the tissue of origin). This characterisation led us to the observation
that both in vitro and in vivo, CSCs show increased replicative potential, as they constantly expand in
culture. The consequent analysis of the growth properties of these cells by a label retaining assay with
the PKH26 dye confirmed that indeed CSCs possess increased proliferating capacity, as they were found
also in the non-label retaining (PKHlow, PKHneg) fractions. On the contrary, normal SCs remained in a
quiescent or slowly proliferating state, and could be found only in the label-retaining PKHhighfraction.
Based on the property of normal SCs to remain mainly quiescent, we took advantage of the PKH26
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label-retaining assay to isolate a subfraction of cells (PKHhigh) that had retained the dye after 2 weeks
in culture, and we confirmed that this subfraction is highly enriched in SCs, both in normal and tumour
samples by limiting dilution transplantation. The visualisation of the cell division of PKHhighcells by
time-lapse analysis during mammosphere formation showed that WT SCs mainly generate two cells with
different proliferative fate: one cell that remains quiescent (the putative SC) and one that carries on
proliferating, giving rise to the bulk of the mammosphere (progenitor cell). Indeed, this was consistent
with the fact that the proliferating fractions of the PKH-sorted cells (PKHneg) do not contain SCs. On
the contrary, tumour SCs generate two daughter cells with the same proliferation potential and they can
be found both in the non-proliferating and in the proliferating PKH subfractions. This, together with
the observation that CSCs expand in number in culture, suggests that not only tumour SCs are able
to divide symmetrically, but they have increased proliferative potential compared to WT SCs. These
observations also correlated with the distribution of the cell fate determinant Numb on the cell membrane
of dividing SCs. Numb was asymmetrically distributed on the cell membrane of dividing WT SCs, but was
symmetrically partitioned in dividing CSCs. Altogether, these data suggest that an important acquired
feature of CSCs is their ability to undergo several rounds of cell division without losing their self-renewal
potential; furthermore, these cells adopt a symmetric mode of division that results in the amplification of
the CSC pool.
Importantly, these acquired features in CSCs are not accompanied by the loss of the developmental
potential, as their ability to form more differentiated cells is still maintained. In fact, both the mammo-
spheres in vitro and the tumour tissue in vivo are not composed solely of CSCs. This implies that these
cells are able to alternate the use of symmetric and asymmetric cell divisions, thus increasing the stem
cell pool without losing the ability to generate new differentiated cells. Accordingly, the analysis of the
symmetry of CSC divisions by time-lapse and Numb staining revealed that these cells are able to adopt
both modes of divisions. Nevertheless, if we model the formation of tumour mammospheres assuming that
the frequency of symmetric or asymmetric divisions remains constant throughout the sphere formation,
we obtain tumour mammospheres with a predicted number of CSCs that is in fact highly overestimated
compared to the experimentally generated numbers. In light of this, we corrected the modelling of the
proliferative history of normal and CSCs during mammosphere formation based on the number of SCs
that were measured empirically. According to the model reported in fig. 7.1, the relative frequency of
symmetric divisions that a CSC undergoes decreases progressively during mammosphere formation, indi-
cating that the mammosphere itself creates an environment for the SC that influences its behaviour with
mechanisms that are yet unknown, favouring asymmetric cell divisions.
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Figure 7.1: Modelling the proliferative history of normal and cancer SCs.
The model represents the kinetics of cell divisions during the clonal expansion of one normal (upper
panel) or ErbB2-tumour (lower panel) mammary initiating cell. Each (WT or tumour) scheme reports
the proliferative history of one mammary initiating cell (upper part), the projected cellular composition of
the formed mammosphere (middle part), and the progressive decrease of the PKH fluorescence intensity
(PKH gradient). Mathematical modelling of WT or ErbB2 SC divisions within mammospheres was based
on two predicted values: i) the number of SCs within each of the three PKH-subsets of the mammosphere;
and ii) the number of prior divisions for each of the predicted SCs (proliferative history) within each PKH
subset. These predictions were elaborated from the experimental data. The proliferative history of the WT
mammary initiating cell was modelled to obtain one mammosphere containing 1 PKHhigh SC, through 1
asymmetric division (bold black arrows). The proliferative history of the tumour mammosphere initiating
cell was modelled to obtain a mammosphere containing 7 SCs, of which: 2 in the PKHhigh subset (2
cell divisions), 4 in the PKHlow (4-7 divisions) and 1 in the PKHneg (10 divisions). To accommodate
these constrains, the model incorporated the following features: i) 1 symmetric division of the tumour
mammosphere initiating cell (red arrow) to generate two daughter SCs with equal proliferative potential
(D1 and D2; only the expansion of D1 is shown in the graph); ii) 1 symmetric division of D1 (red arrows)
to generate 1 PKHhigh SC and 1 SC that divided further to generate PKHlow and PKHneg SCs; iii)
alternation of 2 symmetric and 3 asymmetric (black arrows) divisions to generate 2 PKHlow SCs and 1
SC that proliferated further; and iv) 3 additional rounds of asymmetric divisions to generate 1 PKHneg
SC. The resulting model predicts that the frequency of symmetric divisions decreases with the growth of
the mammosphere. Pr: Progenitors (overlapped progenitors project their expansion).
Another important acquired feature of CSCs is their extended replicative potential. In fact, while
normal SCs can only undergo a restricted number of self-renewing divisions in vitro and exhaust in
culture, and can only be serially transplanted for six to seven times(Daniel et al., 1968), tumour SCs
are virtually immortal and can be indefinitely passaged in culture. This property, together with their
increased frequency of symmetric divisions, explains the continuous geometric expansion of CSCs in vivo
84
7.1 Self-Renewing Divisions in Mammary SCs 7 DISCUSSION
and in vitro. On the other hand, their ability to divide asymmetrically and generate differentiated progeny,
explains the continuous growth of the tumour mass and its cellular heterogeneity.
7.1.2 p53 and Regulation of SC Polarity
We have shown that SCs can divide symmetrically or asymmetrically and that the regulatory mechanisms
that govern these processes appear to be altered in cancer SCs, that preferentially adopt a symmetric mode
of division, thereby expanding in number and giving rise to ever-growing tumour masses. The mechanism
by which SC divisions are regulated may involve asymmetric distribution of cell fate determinants (for
example the Par proteins, Notch or Numb) or other cytoplasmic components like mRNAs. We have
shown the involvement in this process of the tumour suppressor p53, which suggests that the cell stress
and DNA-damage that result from proliferation may also play a role on the outcome of cell divisions.
Interestingly, p53 has been recently found to be a key regulator of the reprogramming process that drives
differentiated adult cells into a pluripotent stem-like state (iPS cells) by expression of different factors
like Myc, Klf4, Oct4 and Sox2 (Utikal et al., 2009; Marion et al., 2009; Li et al., 2009; Hong et al.,
2009; Kawamura et al., 2009). In particular, the absence of p53 is an important factor in enhancing the
frequency of reprogramming of iPS cells.
The absence of p53 on mammary SCs increases their replicative potential and determines a switch in
their mode of division from asymmetric to symmetric. The outcome of this is that p53 KO SCs behave
like tumour SCs in terms of SC expansion, both in the mammary gland in vivo and in mammospheres in
vitro.
These observations are in agreement with published data showing that in the presence of a p53 mutant
with increased activity, mammary SCs undergo rapid exhaustion and have limited regenerative potential
upon serial transplantation (Gatza et al., 2008). These data show how p53 has a role in the regulation of
self-renewal in mammary SCs, and acts by maintaining their number constant in the mammary gland by
imposing an asymmetric mode of division, thereby limiting the SC expansion.
Interestingly, this effect appears not to be restricted to mammary SCs, as the absence of p53 also
increases self-renewal of neural SCs (Meletis et al., 2006), suggesting that its role in the regulation of SC
division is common to different tissues.
7.1.3 Loss of p53 and Tumour Initiation
p53 is lost or functionally impaired in a vast number of cancers of various tissues. In the mammary
gland, genetic alterations of the p53 locus result in an increased incidence of breast tumours. In the
mouse, the absence of p53 results in the formation of an apparently normal mammary gland (Jerry et al.,
1998) and p53 KO mice rarely develop mammary tumours, probably due to the premature development
of lymphomas. Nevertheless, somatic inactivation of p53 in the mammary gland (Liu et al., 2007b) or
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transplantation of p53 KO mammary tissues in WT mice result in the formation of mammary tumours
with high incidence (Jerry et al., 2000; Kuperwasser et al., 2000). These observations suggest that an
increase in the number of SCs due to p53 inactivation primes the mammary tissue to the formation of
tumours, possibly by increasing the number of putative targets of transformation. Notably, amongst
common risk factors for mammary tumour formation there is also the mass of the mammary gland itself,
which is likely to correlate with the SC content (Trichopoulos et al., 2008).
In the MMTV-ErbB2 breast cancer model, the increased proliferative potential and symmetric SC
divisions can be explained by the absence of a functional p53 pathway. We have shown, in fact, that in
tumour mammospheres the p53-mediated response to stress is functionally attenuated compared to WT
samples. It is therefore reasonable to conclude that the behaviour of tumours in terms of proliferating
potential and SC division can be attributed to the absence of p53. In fact, we have shown that in these
cells, the restoration of the levels of p53 by inhibition of its degradation pathway (with Mdm2-inhibitor
Nutlin-3) results in a rapid exhaustion of the tumour mammospheres in culture due to the recovery of
the asymmetry of SC division and the progressive reduction of the number of cancer SCs in tumour
mammospheres (Fig. 7.2).
Figure 7.2: Modelling the role of p53 in tumour development.
In the absence of a functional p53 SCs divide symmetrically and contribute to the formation of a tu-
mour mass. Restoration of p53 levels with Nutlin-3 treatment switches SC division from symmetric to
asymmetric (adapted from Pasi et al., 2010).
This effect was also confirmed in vivo, as tumour mammospheres treated in vitro with Nutlin-3 gen-
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erated tumours with reduced volumes compared to controls. Interestingly, this was not accompanied by
an apoptotic response or by the reduction of proliferating cells, suggesting that the consequence of the
restoration of p53 on the tumour mass is to be attributed solely on its effect on SC divisions.
Because tumour expansion is regulated by the proliferative potential and the mode of division of CSCs,
and the presence of p53 ensures a tight control on these processes, the possibility to reactivate of the p53
pathway has important therapeutic implications in those cancers where it is altered. Recently, several
groups have shown that re-expression of p53 in p53-null tumours results in an apoptotic or senescent
response and in the rapid regression of the malignancy (Xue et al., 2007; Ventura et al., 2007; Martins
et al., 2006). However, in tumours where p53 is present in its WT form, other mechanisms may be
responsible for the impairment of its function. In our tumour model, a constitutively active ErbB2 acts
on the localisation of Mdm2, an E3 ubiquitine-ligase that targets p53 for degradation, enhancing its
activity. Indeed we have shown that the treatment of MMTV-ErbB2 mice with the Mdm-2 inhibitor
Nutlin-3 and the consequent disruption of the p53-degrading pathway in tumour tissues results in an
increase in the latency of tumour development and in a reduction of the mass. This is also accompanied
by a reduction in the number of CSCs, the putative targets of new anticancer strategies. Favourable
therapeutic outcomes can therefore also be achieved by enhancement of the p53 pathway also in the
presence of WT p53 alleles, but with attenuated signalling, a situation that is common to approximately
50% of human cancers.
7.2 Myc and Self-Renewal
We have shown that p53 regulates self-renewing divisions in SCs, and imposes asymmetry in the cell
fate of the two daughter cells. In the absence of p53, however, the asymmetry is lost and two daughter
cells with identical stem properties are formed, thus amplifying the SC pool. Interestingly, the impaired
function of p53 is responsible for the increased proliferative potential and the symmetric division in cancer
SCs derived from MMTV-ErbB2 tumour tissues, as its restoration is sufficient to revert the phenotype.
These findings have very important therapeutic implications for the establishment of new anticancer
therapies aimed at the enhancement of the p53 function in the presence of WT alleles with impaired
activity. Nevertheless, the mechanism with which p53 regulates SC self-renewal is still unknown, but of
great interest for those cancers that lack a normal p53 allele but might follow similar pathways that result
in the deregulated activity of SCs. We have investigated the mechanisms that govern SC self-renewal
and symmetry of division, and have found that deregulated Myc may act as a putative effector for the
increased self-renewal and symmetric divisions in CSCs.
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7.2.1 The p53-Myc Axis in the Regulation of SC Self-Renewal
A role for Myc in regulating SC self-renewal has been described in several systems (Betschinger et al.,
2006; Kerosuo et al., 2008; Nagao et al., 2008; Zheng et al., 2008).
Interestingly, we found high levels of Myc expression in our mammosphere models with increased self-
renewing abilities (p53 KO and tumour mammospheres), which are characterised by absent or functionally
impaired p53. This is consistent with the existing evidences for a p53-mediated negative regulation of the
transcription of the Myc gene(Sachdeva et al., 2009; Ragimov et al., 1993; Ho et al., 2005). The function of
p53 in favouring asymmetric cell division may therefore proceed through the inhibition of its target Myc,
and Myc activation in the absence of a functional p53 may be responsible for the induction of symmetric
divisions in cancer SCs as depicted in the model in fig. 7.3. We have investigated this pathway to confirm
that the regulation of self-renewal and cell divisions in SCs is ascribable to the p53-Myc axis.
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Figure 7.3: The absence of p53 in cancer and p53 KO SCs promotes symmetric divisions
through activation of c-Myc.
Modelling of the effect of the absence of p53 on the regulation of Myc expression and its effect on SC
division. In the absence of its negative regulator p53, Myc is overexpressed and induces SCs to divide
symmetrically, a situation that is common to p53 KO and MMTV-ErbB2 SCs.
In this scenario it is reasonable to hypothesise, but still remains unshown, that the restoration of
p53 levels in tumour SCs by Nutlin-3 treatment results in the inhibition of the expression of Myc and
subsequently a switch in the mode of SC division from symmetric to asymmetric (fig. 7.4).
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Figure 7.4: Restoration of p53 levels by Nutlin-3 treatment results in downregulation of Myc
and asymmetric SC division.
Treatment of MMTV-ErbB2 SCs with Nutlin-3 restores the levels of p53 expression. This in turn results
in the switch of the SC mode of division from symmetric to asymmetric. We have shown that Myc is
responsible for the symmetric divisions of mammary SCs, it is therefore reasonable to hypothesise that
Nutlin-3 treatment indirectly induces downregulation of Myc.
Reverse genetics approaches to confirm the function of Myc in controlling SC self-renewal resulted
ineffective due to the fact that the silencing of Myc expression was not compatible with cell viability. Our
approach was therefore an indirect one, and was aimed at the uncoupling of the p53 and Myc pathways in
the regulation of SC divisions in tumour mammospheres. To achieve this, we rendered the expression of
Myc independent from the p53-mediated regulation by infecting the cells with a lentiviral vector carrying
the Myc protein under a strong promoter. We then treated the cells with Nutlin-3 to restore the levels of
p53. Because the exogenous Myc was not negatively controlled by p53, we expected its levels to remain
high, and therefore to induce symmetric division thus rendering the treatment with Nutlin-3 ineffective
(fig. 7.5).
89
7.2 Myc and Self-Renewal 7 DISCUSSION
p53
c-Myc
SC
SC
Pr.
SC
SC
Nutlin-3
+
Mdm2
c-MycER
Exogenous c-Myc
Uncoupling of the p53-Myc pathways
Figure 7.5: Uncoupling of the p53 and Myc pathways in the regulation of SC divisions.
The expression of exogenous Myc renders the treatment with Nutlin-3 ineffective on SC division, as
restored p53 cannot act on the regulation of Myc under a strong promoter. This results in the maintenance
of a symmetric mode of SC division independently of the levels of p53 expression.
Indeed, we were able to demonstrate that exogenous Myc expression renders the treatment with Nutlin-
3 ineffective, suggesting that indeed it acts downstream to p53 itself. In the context of cancer SCs, these
are novel and interesting findings that may broaden the number of available treatments that can target
specifically SCs, that may not be targeted by conventional anticancer treatments. To this end it will be
of great interest to investigate if this mechanism that governs self-renewal in mammary CSCs is common
also to other tumour types.
7.2.2 Different Thresholds of Myc Expression Have Different Effects on SCs
Deeper analysis on the involvement of Myc in self-renewal regulation led us to identify two diametrically
opposed situations resulting from the overexpression of Myc in mammary SCs. In fact, depending on the
levels of Myc expression we found that SCs responded either by activating a p53-mediated checkpoint (high
levels) or by increasing their self-renewing properties (low levels). We have shown that expression of Myc
at high levels triggers in SCs an apoptotic checkpoint associated with phosphorilation and stabilisation
of p53, and the expression of p21/WAF1, a p53 transcriptional target(el-Deiry el Deiry, 1993) . This
phenotype was indeed consistent with an oncogene-induced, p53-dependent apoptotic checkpoint (Ray
et al., 2006; Halazonetis et al., 2008). Accordingly, the absence of p53 protected the SCs from apoptosis
when expressing high levels of Myc. The robust DNA-damage response in the presence of high levels of
Myc is consistent with the oncogene-induced DNA replication stress model, which postulates that aberrant
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oncogene activation induces DNA replication fork collapse, formation of DNA double-strand breaks and
genomic instability targeting preferentially specific sites in the genome that are referred to as common
fragile sites (Halazonetis et al., 2008; Di Micco et al., 2006; Bartkova et al., 2006). Indeed, high levels of
Myc have already been shown to induce genomic instability (Mai et al., 1996).
Conversely, low levels of Myc expression resulted in increased self-renewal and lifespan of normal
mammary SCs, as they continuously expanded in culture and could be passaged virtually indefinitely.
Interestingly, low levels of Myc activation did not induce the expression of checkpoint genes such as p53,
or p21/WAP, suggesting that low levels of Myc do not act through the activation of p53. Accordingly, p53
was perfectly functional, as activation of stress induced its phosphorilation and stabilisation. Finally, p53
KO mammospheres transduced with the Myc lentivirus did not acquire additional self-renewing abilities
upon expression of low levels of Myc. These observations suggest that low levels of Myc expression do not
act through the activation of p53, and do not create selective pressure to lose the p53-mediated checkpoint.
In fact, they are not sufficient to activate a p53-dependent oncogene-induced checkpoint.
A dual effect for Myc depending on the levels of its expression had been described previously by
Murphy et al. by using a conditional mouse model for the expression of Myc in the Rosa26 locus, which
allows for low levels of expression. Expression of low levels of Myc induced hyperproliferation but not
apoptosis in several tissues including pancreas, liver, kidneys and lung. On the contrary, when expressed
at high levels in a different model, Myc induced growth arrest and activation of ARF (Murphy et al.,
2008). These and our observations show that the expression of Myc can have different effects depending
on its expression levels. Interestingly, very preliminar data show that induction of high levels of Myc
expression in MMTV-ErbB2 tumour SCs are sufficient to induce growth arrest of tumour mammospheres,
indicating that the sensitivity to Myc thresholds is maintained in transformed SCs despite them already
exhibiting higher levels of Myc expression compared to WT SCs (data not shown).
From a biological point of view, Myc does not transform normal SCs, as transplantation of these cells
into recipient mice resulted in the formation of normal tissues two months after engraftment. Currently,
transplanted mice do not show any formation of palpable masses in the transplantation sites (7 months).
Interestingly, us and others have shown that p53 KO SCs transplanted into the cleared fat-pad of recipient
mice form normal mammary tissues. However, it has been reported that these tissues undergo spontaneous
transformation with a latency of about 50 weeks without any hormonal stimulation (Jerry et al., 2000).
Because the absence of p53 and overexpression of Myc seem to be part of one single mechanism, it
is reasonable to hypothesise that tumour formation in low Myc-expressing cells may occur with long
latency, or even, due to the tumour-suppressor activity of p53 that is still present and active in these cells,
it may even take longer than in the absence of p53.
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7.3 Dual Effect of Myc on Stem and Progenitor Cells
The rapid expansion of the Myc-expressing mammosphere cultures suggests that each mammosphere
contains more than one SC. Two possible mechanisms can account for this phenotype depending on
whether Myc acts on SCs or progenitors. We have shown that Myc is responsible for the increased self-
renewal in tumour SCs and p53 KO SCs, and it is reasonable to believe that a similar effect is found in
WT SCs with enforced expression of Myc at low levels. Nevertheless, we could not exclude that Myc also
acts on progenitor cells by reprogramming them into new SCs.
7.3.1 Effect of Myc on Mammary SCs
We have shown that Myc increases the lifespan of WT SCs if expressed at low levels, and that it also
increases their replicative potential. The ever-expanding mammosphere culture in low Myc-expressing
cells suggests that the SC pool is in continuous expansion. This is reflected in the continuous expansion
of mammosphere initiating cell at every passage. Indeed we have demonstrated (Cicalese et al., 2009)that
mammosphere-initiating cells and SCs coincide in normal and tumour mammospheres. We can therefore
assume that the number of mammosphere-initiating cells in low Myc-expressing mammospheres corre-
sponds to the frequency of SCs per mammosphere (~15 per sphere). We have shown that the expansion
in the number of SCs is ascribable to a switch from an asymmetric to a symmetric mode of division of
SCs. Indeed we show that a similar mechanism is activated upon expression of low levels of Myc. In fact,
isolation of PKHhighcells and visualisation of the first few divisions during mammosphere formation led
us to the conclusion that whereas SCs infected with a control vector showed proliferative asymmetry in
the two daughter cells, the expression of Myc was sufficient to induce a switch in the mode of division, and
SCs mainly generated two daughter cells with analogous proliferating capacities. Indeed, we confirmed
this also by staining the dividing SC with an antibody that recognises the fate determinant Numb and
found that it is indeed asymmetrically distributed in WT SCs but uniformly localised on the membrane
of dividing SCs that express low levels of Myc. Interestingly, recent evidences have been published to
show that Numb regulates the activity of p53, therefore representing an upstream link to the p53-Myc
axis in the regulation of SC division (Colaluca et al., 2008). It will be of great interest to study this axis
in relation to SC division regulation.
7.3.2 Effect of Myc Expression on Progenitor Cells
Myc enhances the efficiency of reprogramming of somatic cells into pluripotent cells by about a thousand-
fold(Nakagawa et al., 2008). Induction of the pluripotent state requires genome-wide demethylation
(Mikkelsen et al., 2008), which is difficult to achieve (Kim et al., 2010) therefore explaining the low
frequency of reprogramming events in the transition from fibroblasts to iPS cells. It is reasonable to
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assume that reprogramming of somatic cells to SCs of the same tissue type may not require such extensive
genome-wide demethylation and might, therefore, be more readily achievable. To investigate the effect of
low Myc expression on progenitor cells and its contribution to the increased self-renewing abilities of WT
mammospheres expressing Myc, we deprived the mammosphere culture of the SCs by fractionating these
cells with the already described PKH assay. We have demonstrated that in WT samples PKHhighcells are
enriched in SCs (1 in 3), and that the PKHnegdo not contain any cells with stem properties, however, we
refer to PKHneg cells as progenitors but the formal demonstration that they are progenitors is still lacking
in our system. Nevertheless, evidence obtained using human mammary PKHneg cells show that upon
plating in a collagen-based matrix (which allows differentiation), these cells can only form either epithelial
or myoepithelial colonies (never mixed colonies as expected with SCs). Under the same experimental
conditions, PKHhigh cells form mixed colonies, confirming that they are indeed SCs (Pece et al., 2010).
Strikingly, we observed that upon expression of low levels of Myc, PKHneg progenitor cells were able
to survive anoikis and acquire self-renewing abilities. In fact, whereas control infected progenitors only
formed small irregular aggregates that had no self-renewing abilities and could not be passaged in culture,
low Myc-expressing progenitors formed mammospheres that could be serially passaged and possessed
increased growth kinetics compared to WT mammospheres. Strikingly, we measured the regenerative
potential of these cells by transplantation in cleared fat-pads of recipient mice and we found that these
cells are able to form, albeit with low frequency, a normal mammary gland. Indeed their regenerative
potential together with the acquired self-renewing abilities suggested that progenitor cells had undergone
a cellular reprogramming that led to the formation of SCs. Interestingly, like iPS cells can be induced
to differentiate into different tissues (Wernig et al., 2008; Hanna et al., 2007; Dimos et al., 2008), repro-
grammed mammary progenitors can differentiate and give rise to a normal mammary gland, a process
that is probably accompanied by epigenetic alterations and downregulation of the exogenously expressed
Myc protein.
These data show that the effect of Myc on mammary epithelial cells acts on two levels: by inducing
symmetric divisions in SCs thus expanding their pool, and by stochastically reprogramming progenitor
cells into new SCs (Fig.7.6).
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Figure 7.6: Modelling of the effect of Myc on mammary epithelial cells.
Schematic representation of the SC division in normal cells (asymmetry of division) and in cells where Myc
is overexpressed at low levels (symmetry of division and stochastic reprogramming). Normal SCs divide
asymmetrically to generate a SC that remains quiescent and a progenitor cell that is able to proliferate
and differentiate. When Myc is expressed at low levels, but still higher than the basal levels, SCs undergo
symmetric divisions generating two daughter cells with stem properties. Moreover, the expression of Myc
is sufficient to induce stochastic reprogramming of progenitor cells into new SCs. Together, these two
mechanisms account for the continuous expansion of the SC pool in low Myc-expressing samples.
Indeed, newly reprogrammed SCs are subject to the same induction of symmetric divisions in response
to low levels of Myc expression. In fact, if the only effect of Myc was that of reprogramming progenitors
into SCs, then these cells would behave as WT mammospheres in serial re-plating experiments, and
progressively exhaust or show a slight increase in the yield of mammospheres compared to normal SCs,
proportional to the frequency of reprogramming in progenitors, which is very low. On the contrary, the
experiments demonstrate that Myc, on top of its reprogramming effect, confers new properties to SCs,
regardless whether they are obtained from PKHneg cells or WT mammospheres: Myc, in fact, increases
self-renewal (measured by the increased number of mammospheres at each passage, which is due to its
ability to increase the frequency of symmetric divisions) and confers immortality (based on the fact that
the mammosphere cultures do no exhaust). In summary, data suggest three separated effects of Myc:
i) reprogramming of progenitors, ii) increased self-renewal of SCs (increased frequency of symmetric
divisions), iii) immortalisation of SCs.
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It still remains to be demonstrated whether these effects are part of the same phenotype (e.g. whether
they are hierarchically linked) or whether they are three (mechanistically) independent effects. However,
these findings challenge the current postulation of the cancer stem cell theory that identifies the target
of transformation with normal SC, as the first stages of cellular immortalisation may induce progenitor
reprogramming if they alter the expression of specific genes. The best fitting theory for cancer development
to the model that we postulate is therefore the interconversion model, which stands between the clonal
evolution model and the cancer SC theory, and takes into consideration that any cell may be the target
of transformation and not only SCs, as the cancer SC theory postulates. On the other hand, targeting
of any cell in a given tissue may proceed by reprogramming of this cell into a CSC with stem properties,
thus accomodating recent evidences for the existence of SCs in the tumour bulk. From a clinical point of
view, these findings have tremendous implications, as the eradication of tumours may require not only to
target specifically the CSCs, but also those mechanisms that may induce reprogramming of tumour cells
into cells with CSC properties.
7.3.3 Myc-Induced Reprogramming and Genomic Instability
The reprogramming of adult cells into SCs has been extensively developed in the last few years and has
raised hopes for the treatment of several human diseases. The reprogramming involves the expression of
different genes and Myc is typically included in this mix. However, expression of oncogenes leads to DNA
replication stress and genomic instability that activate a p53-dependent response. We wondered if the
reprogramming that results from the expression of proto-oncogene Myc can be associated with genomic
instability and to this end we analysed five reprogrammed clones for genomic aberrations.
Interestingly, we show that all the analysed cloned had genomic alterations in regions of known fragile
sites, based on the homology with the human common fragile sites (Helmrich et al., 2006). Given that
we only analysed a quarter of the mouse genome, it is reasonable to assume that with this protocol one
could only obtain reprogrammed SCs with genomic rearrangements. Two mechanisms may contribute to
the observed genomic instability. The first may involve oncogene-induced DNA replication stress and the
presence of deletions in common fragile sites in two of our clones suggest that this mechanism may be
relevant(Halazonetis et al., 2008; Bartkova et al., 2006; Di Micco et al., 2006). The second mechanism
may relate to the reprogramming process itself. Reprogramming requires DNA demethylation, which is
currently thought to involve induction of DNA damage and subsequent DNA repair-mediated replacement
of methylated cytosines by unmethylated cytosines (Gehring et al., 2009; Mikkelsen et al., 2008). Perhaps,
the single-stranded DNA breaks generated during DNA repair lead to genomic instability in replicating
cells, whereas DNA demethylation in primordial germ cells occurs in the G2 phase of the cell cycle
(Hajkova et al., 2008).
A key question is whether a few genomic aberrations can compromise the function and utility of
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reprogrammed SCs. In our case, the mammary SCs were capable of repopulating cleared fat pads and none
of the mammary glands derived from these cells have become cancerous so far. This would be consistent
with the apparent transient nature of the genomic instability during the reprogramming process itself. It
would now be interesting to examine if iPS cells also exhibit genomic aberrations. Because reprogramming
of somatic cells to pluripotent SCs is more efficient in a p53 KO background (Utikal et al., 2009; Hong
et al., 2009; Kawamura et al., 2009; Marion et al., 2009), we speculate that reprogramming of those
cells is also associated with some form of genomic instability. Indeed, these finding challenge the use of
reprogrammed SCs in the clinic and may open new questions on the true identity of these cells.
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